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This research explored quantitative relationships (QSPKR) between different molecular 
descriptors and pertinent, systemic PK properties for 14 calcium channel blockers (CCB). 
Physicochemical properties (PC) such as molecular weight (MW), molar volume (MV), calculated 
logP (clogP), pKa, calculated logD7.4 (clogD), % ionized at pH 6.3 and pH 7.4, hydrogen bond 
donors (HBD), hydrogen bond acceptors (HBA), and number of rotatable bonds (nRot) were chosen 
as possible predictor variables for systemic PK properties for CCB, obtained from pertinent literature, 
assessing the PK of CCB after intravenous administration to healthy humans. 
All PC properties and molecular descriptors were computed using ACD-solubility/DB 12.01. 
Total body clearance (CLtot), steady-state volume of distribution (Vdss), total area under the plasma 
concentration-time profile (AUCoo), terminal half-life (t1/2), and fraction of drug excreted unchanged 
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in urine (fe), if available, were obtained or derived from original references, exclusively from IV 
studies that administered CCB to healthy human volunteers. Several articles focused on drug 
interactions with grapefruit juice or the impact of renal/hepatic dysfunction, and in such cases, data 
from the healthy control group were used. Each study was evaluated for study design, PK sampling 
schedule, bioanalytical and PK analysis methods before inclusion into the final database. 
The assumption of linear systemic PK was verified by assessing AUCoo versus (IV) dose. 
Plasma protein binding information was collected from in-vitro experiments to obtain the fraction 
unbound in plasma (fu). Unbound volume of distribution at a steady state (Vdss
u
), unbound total 
(CLtot
u
), renal (CLren
u
), and non-renal clearance (CLnonren
u
) were estimated and compared with the 
relevant physiological references for Vdss
u
 (plasma volume, blood volume, extracellular and 
intracellular spaces, total body water and body weight) and for the unbound clearances (liver blood 
flow, renal plasma flow, and glomerular filtration rate, GFR). Final PK property values were 
obtained by averaging across available studies. The distribution of both PC and PK properties were 
evaluated, and correlation matrices amongst PC properties were constructed to assess for 
collinearity. If two PC descriptors were found to be collinear, i.e. r,  ≥ 0.8, only one of them was 
used in the final univariate analysis. Finally, univariate linear regression of all PK variables versus 
each molecular descriptor was performed; any relationship with p<0.05 and r
2≥0.30 was considered 
to be statistically significant. 
The PC properties of the final 14 CCB were reasonably normally distributed with few 
exceptions. Overall, CCBs are small (MW range of 316-496 Da), basic and lipophilic (logD7.4 range 
of 1.5-5.1) molecules. On the other hand, for the PK properties, the distributions were found to be 
skewed with high standard deviations. Thus, all PK variables (except fu) were log-transformed. 
Although CCB are mostly highly plasma protein bound (fu range of 0.2-20%), they are characterized 
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by extensive extravascular tissue distribution (Vdss range of 0.6-20.4 l/kg) and high, mainly 
metabolic, clearance (CLtot range of 3.7-131.7 ml/min/kg). Clevidipine is the only CCB undergoing 
extensive, extra-hepatic ester hydrolysis, responsible for the highest CLtot value. Urinary excretion 
for CCB is negligible. Amlodipine is a PK outlier due to its high Vdss (20.4 l/kg) and low CLtot (6.9 
ml/min/kg, due to low hepatic extraction) with fu of 2%. Therefore, the final QSPKR analysis was 
performed including, as well as excluding amlodipine. Excluding amlodipine, the relationship 
between fu and logD7.4 was negative and significant (r
2
 of 0.4, n=12). The relationships between 
CLtot
u
, CLnonren
u
 and CLren
u
 and logD7.4 were found to be positive and significant (r
2
 between 0.6-0.7, 
n=3-12); none of the other PC variables affected any of the clearance terms. Although the 
relationship between Vdss
u
 and logD7.4 was not significant (r
2
 of 0.25, n=12), it showed the expected 
positive slope. In fact, after removing bepridil (the remaining outlier in Vdss
u
), the relationship with 
logD7.4 became statistically significant (r
2
=0.46, n=11). 
The QSPKR obtained in this study for CCB, with logD7.4 being the main PC determinant for 
systemic PK properties, were similar to those previously reported for opioids, β-adrenergic receptor 
ligands and benzodiazepines. However, slope estimates for the relationships of CLnonren
u 
and CLtot
u 
as 
a function of logD7.4 for CCB were higher compared to these previously studied compounds, which 
showed higher sensitivity, most likely as a result of their higher lipophilicity. Overall, lipophilicity 
measured as logD7.4 was found to be a statistically significant and plausible PC determinant for the 
biologically relevant systemic PK properties for CCB and other classes of drugs. 
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1 INTRODUCTION 
1.1.1 Background  
The pharmaceutical industry faces many challenges in discovering and developing new drugs 
for clinical use, costing millions of dollar every year; these costs are expected to increase. Dimasi et 
al.
1
 estimated the cost of development of a single new chemical entity approaching $1 billion. 
Thousands of chemical compounds are tested every year, but only a few drugs reach the market, 
which makes the development of new drugs expensive and time consuming. Thus, one of the major 
challenges in discovery and development is to find a way to reduce the costs. The costs could be 
reduced if pharmaceutical scientists were able to predict or identify undesirable compounds at an 
early stage of drug discovery/development. Therefore, many studies have been performed to 
understand possible reasons behind drug development failures. Lipper et al.
2
 found that 63% of all 
pre-clinical compounds failed due to poor pharmacokinetics (PK) and/or drug toxicity. As a result, 
the early prediction of human PK is very important, and most companies and agencies have their 
own approaches, which they believe is the best way to save time and money. Inter-species 
pharmacokinetic allometric scaling, physiologically-based PK modeling, in-vitro-in-vivo 
extrapolation and quantitative structure pharmacokinetic relationships (QSPKR) are used for the 
prediction of PK in the early stage of development. Each method has its own advantages and 
drawbacks. For example, allometric PK scaling has been used successfully in the prediction of 
human volume of distribution (Vd), however, it may not be useful in predicting total body clearance 
(CLtot), especially when a high fraction of clearance is via drug metabolism.
3
 QSPKR models are 
mathematical equations relating quantitative information obtained from the chemical molecular 
structure to their biological activity and PK property. The aim of this study is to discover the most 
important PC properties that are able to predict human PK properties of the available CCB.   
 
 
5 
 
Calcium (Ca
+2
) plays a major role in various cellular functions such as muscle contraction 
and relaxation, as well as cellular secretion.
4, 5 
CCB interact with the L-type voltage-gated calcium 
channels in cell membranes to modulate the intracellular concentration of calcium.
4
 Contractile 
myofilaments (such as those in cardiac and smooth muscles) are activated when the intracellular 
concentration of Ca
+2
 increases. Excitation–contraction coupling in smooth and cardiac muscles is 
very sensitive to these changes. Therefore, the myocardial and smooth muscle contractility depends 
on the amount of Ca
+2 
coming from the extracellular space. Inhibition of Ca
+2
 influxes to cardiac 
muscles causes negative inotropism, while, in vascular smooth muscle, it causes vasodilation and 
hypotension. As a result, these drugs can be utilized to treat arterial hypertension, angina pectoris, 
congestive heart failure and other cardiovascular diseases.
4, 5 
CCB are among the most widely used 
drugs in the treatments of hypertension and cardiovascular disease that are alone or in some time 
combined with other antihypertensive drugs. However, there are tremendous PK differences in term 
of their clinical use of these compounds. Also there are metabolism differences between certain 
groups of patients, such as in case of nifedipine metabolism.
6
 
 
1.1.2 History of calcium channel blockers (CCB) 
Fleckenstein first discovered CCB in 1963 when he was experimenting with two newly 
synthesized compounds. He reported that these two drugs (verapamil and prenylamine) were able to 
diminish the cardiac contractile force without a major change in action potential, and could be easy 
neutralized by administration of calcium. Thus, he realized that this effect was most probably due to 
interfering with calcium function during the excitation–contraction coupling. Fleckenstein chose to 
study verapamil further because it was more potent than prenylamine.
5
 In 1966, Bender et al.
7
 
conducted a study to examine the effects of verapamil in humans as antiarrhythmic and 
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antihypertensive drug. Fleckenstein discovered nifedipine in 1970, and he introduced the term 
“calcium antagonist” to describe these compounds. CCB were introduced in the market in the late 
1970s and early 1980s namely nifedipine, diltiazem and verapamil. Gallopamil, the methoxy 
derivative of verapamil, was discovered in 1986 and had a higher potency than verapamil. In fact, 
these drugs do not share the same pharmacophore, but they share the same mechanism of action, 
blocking the entrance of calcium into cardiac and smooth muscle. After these discoveries, many new 
CCB were discovered.
9
 Fleckenstein first classified these drugs as calcium antagonist group “A”, 
able to selectively suppress the slow calcium current and not suppress magnesium current. On the 
other hand, those drugs that affect both calcium and magnesium current were classified as group 
“B”. More CCB were discovered and the classification was changed to reflect these new 
discoveries.
9
 Today, CCB are classified broadly into three classes based on their preferential site of 
action (arterial vessels and/or the heart), administration frequency, duration of action and chemical 
structure, namely phenylalkylamines (verapamil), 1,4-dihydropyridines (nifedipine, amlodipine, 
clevidipine, felodipine, isradipine, nimodipine and nicardipine), and benzothiazepines (diltiazem).
4, 
10 
Most of CCB on the market belong to dihydropyridine group, and within subclasses, compounds 
are further separated into first, second and third generation based on their PK and PD properties. 
First generation CCB had many side effects and the second generation came to overcome these side 
effects. Thus, the third generation CCB has the best PK and PD profiles such as long half-life and 
higher tissue selectivity. However, in some cases like clevidipine (third generation CCB), was design 
to have an ultra-short half-life to use it as antihypertensive medication during surgery. Thus, it 
depends on the indication.
10
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1.1.3 Chemical structures of CCB 
Many inorganic cations like manganese and lanthanum can easily interfere with calcium in 
the binding sites, but this binding is nonspecific and nonselective, thus, these cations cannot be used 
for treatments as antihypertensive or antiarrhythmic drugs.
11
 Compounds that are more specific to 
interact with calcium and more selective to smooth and/or cardiac muscle can be used as CCB for 
the treatments of hypertension and cardiovascular disorders. Since 1, 4-dihydropyridine CCB are the 
largest group among the three principal classes of drugs, the focus will be on this class. They have a 
dihydropyridine ring (dialkyl 4-aryl-1, 4 dihydropyridine-3, 5 dicarboxylates) as shown in Figure 
1.1.
10 
 
 
Figure 1.1 General structure of 1,4 dihydropyridine  
 
 
 
The first development in the discovery of this class started in 1951 when khellin was 
discovered in the Langendorff heart preparation. The structure of khellin was studied and modified 
by Bayer Chemical Research Laboratories, which lead to the discovery of 1, 4 dihydropyridine.
12
 
The first drug that was discovered and used in humans was nifedipine, as previously discussed. Love 
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et al.
13
 studied the molecular features that make this class of drugs active as CCB and explored 
which molecular changes could be made to improve their potency. He reported that in a series of 
substituted 2, 6-dimethyl-3, 5-dicarboethoxy-1, 4- dihydropyridines the sequence of activity 
increases with 4-substitution in the sequence H < Me < cycloalkyl < heterocyclic < phenyl and 
substituted phenyl. The presence of the 1, 4-dihydropyridine rings is essential, and N1 in this ring has 
to be bound to hydrogen. Finally, the presence of an ester group at the C3 and C5 was found to be 
optimal. This finding was confirmed by several subsequent studies based on pharmacological and 
radioligand binding studies. The chemical structures for all the CCB drugs that were used in this 
analysis are shown in Figure 1.2.  
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Amlodipine Clevidipine Felodipine 
Dihydropyridines
Isradipine Nicardipine Nifedipine
(a) (b) (c) 
(d) (e) (f) 
 10 
 
 
Dihydropyridines 
Nimodipine 
Phenylalkylamin
e 
(i) 
(k) 
(g) 
(h) 
(j) 
Nitrendipine  
Bepridil  
Fendiline  
Nisoldipine  Nitrendipine  
 11 
 
 
Phenylalkylamine
Verapamil
Benzimidazolyl 
Mibefradil Benzothiazepines
Diltazem
Figure 1.2 Chemical structures of classical 
CCB. 
Dihydropyridines (a-i) 
Phenylalkylamines (j-l), Benzimidazolyl (m) and 
Benzothiazepines (n). 
(l) (m) 
(n) 
 12 
 
Most CCB are administered as racemic mixtures. The in-vivo potency of each 
stereoisomer is different, because the metabolism of these drugs by cytochrome P-450(3A) is 
different for each isomer, resulting in stereo-selective drug metabolism and disposition. In most 
cases, one form is active and the other form is inactive or slightly active with respect to blockade 
of calcium channels. For example, for verapamil, the (-)-stereoisomer is more potent in the 
blockade of L-type voltage calcium channels in cardiac tissue and more potent as negative 
inotropic agent compared to the (+)-stereoisomer. The (-) isomer of verapamil is less available if 
the drug was administered by oral route because it has higher first-pass metabolism compared to 
the (+) isomer. However, there are two drugs (nifedipine and diltiazem) that do not have a chiral 
center; so, they are not administered as racemic mixtures.
14 
 
1.1.4 Quantitative-structure pharmacokinetic relationships 
QSAR/QSPKR modeling is the process where molecular properties and descriptors of 
chemical structures are quantitatively correlated with biological activity or PK properties, such 
as clearance and Vd. QSAR simply asks: do compounds that share the same or similar biological 
activity have something similar about their chemical structures? Each model has underlying 
assumptions that primarily depend on the question that this model tries to answer. For example, 
when the goal of the model is to quantify structural similarity that imparts biological activity, the 
assumption is that other untested molecules with similar chemical features should produce 
similar activity.   
A significant amount of information can be obtained from chemical structures that can be 
quantitatively correlated with biological activity, but which PC properties should be calculated 
and used to build a QSAR model? Based on the question that the model tries to answer, there are 
 13 
 
different numbers of PC properties that should be used and there are several software packages 
that can help in obtaining these PC values. The PC properties to be measured are chosen after 
evaluation of a number of studies in the literature, and when strong evidence is found that these 
PC properties may affect the disposition of drugs. For example, Lipinski et al.
16
 published a 
study after in-vitro evaluation of the solubility and permeability of 2200 compounds in which 
they had examined the structural properties. They came up with the "Rule of Five", or what is 
now known as the "Lipinski rules", after clear trends were observed between PC properties, 
solubility, and GI permeability of these compounds. This rule indicates that drugs that have 
molecular weight (MW) of more than 500 (D), logP value of more than 5, more than 10 
hydrogen bound acceptors, and more than 5 hydrogen bound donors, are most likely to have poor 
oral absorption. The Lipinski rule is based on solid research and strong rationale, i.e., a higher 
number of hydrogen bonds increases the solubility of the drug in the gastrointestinal tract (GIT), 
making it more difficult for the compounds to break these bonds and penetrate into and through 
the lipid bilayer membrane of the GIT by passive diffusion.
15, 16
 Veber et al.
17
 conducted a study 
to examine the oral bioavailability in rate of 1100 drug candidates studied at GlaxoSmithKline. 
They found that the molecular flexibility, polar surface area (PSA), and hydrogen bond acceptors 
and donors (hydrogen bond counts) are important determinants of increasing oral bioavailability. 
They concluded that compounds are most likely to have good oral bioavailability when the 
number of rotatable bonds is ≤10, the value of PSA ≤140 Å2 or the number of hydrogen bond 
acceptors and donors are ≤12. 
Molecular properties are normally estimated using a variety of commercially available 
software, such as SYBYL, ACD lab, Dragon and HYBOT. Each software calculates several 
different 1D, 2D, 3D descriptors that may help to build a predictive QSAR model.
18, 19
 Their 
 14 
 
estimates actually depend on numerous factors, such as the number of compounds that were used 
in the original model validation, wide distribution between low and high-end values of the 
descriptors i.e., (MW, clogP, clogD, etc.) that were used, and sufficient coverage of chemical 
groups. Values of clogP or clogD are considered very important in QSAR and using incorrect 
values could lead to potential errors.
18, 20
 Values of clogP and clogD are calculated by software 
because it is fast, cheap and highly accessible. Each software estimates these values based on 
experimental data of large number of databases, thus the clogP are most likely to be accurate for 
known structures. On the other hand, these in-silico estimates are not accurate like the one 
measured in the laboratory especially if it is for new compounds or derivatives.
20 
Unfortunately, 
measurements of these properties (logD and logP) in laboratory are not always accessible, and 
the experimental techniques are very time consuming. There are many other difficulties like the 
presence of impurities with the compound or low solubility, or the need for co-solvents.
20
  
A quantitative structure pharmacokinetic relationship (QSPKR) is a specific type of 
QSAR, which focuses only on the correlation between chemical structures and PK properties.
21
 
The underlying assumption of QSPKR is that variations in the PK properties of a series of 
compounds are dependent on differences and variations in their structural, physical, and/or 
chemical properties that are mainly obtained from chemical structures. QSPKR is an important 
approach in drug discovery and several models were developed to be used in this field.
21
   
Badri
21 
developed a QSPKR model for predicting human systemic PK properties of three 
pharmacological classes of drugs. These classes were opioids, β-adrenergic receptor ligands (β-
ARL) and β-lactam antibiotics (β-LAs). Human and animal PK databases were used in this 
analysis to understand the relationship between molecular descriptors and PK behavior of the 
drugs. In this analysis, it was found that lipophilicity (logD7.4) and molecular weight (MW) were 
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the most important molecular properties affecting the biologically relevant systemic PK 
properties. Furthermore, their QSPKR model were able to predict fu, Vdss
u
, Cltot
u
 and CLnonren
u
 
for molecules with logD7.4 > -2.0 and MW < 350 D. On the other hand, there were some 
difficulties in predicting these values for compounds with logD7.4 < -2.0 and MW > 350 D (e.g., 
β-LA) because most of these drugs require specific drug transporters for distribution and 
excretion.
21
 The importance of this finding is that chemists know how to alter these molecular 
properties (logD7.4 and MW) of compounds. Therefore, many new drugs could be discovered 
and/or existing drugs could be modified to develop improved drugs. In addition, the results were 
generalized across different classes of drugs that have dissimilar PC properties. Interestingly 
enough, it is not necessary to synthesize a molecule to predict PK properties, which is a major 
advantage in this method.
21 
Scientists are looking to increase vascular selectivity of CCB by different approaches to 
reduce the side effects of these drugs. However, it is very difficult, because the human body has 
various subtypes of Ca
2+
 channels with different tissue distribution. 1, 4-DHP is the largest group 
of CCB that have been developed in order to obtain higher tissue selectivity. The logical reason 
behind this superior vascular selectivity of DHP is that this group is bound preferably to 
inactivate voltage-gated calcium channels, which are available more in smooth muscle compared 
to cardiac muscle. In fact, cardiac muscle undergoes only brief periods of depolarization through 
the cardiac cycle, thus having brief inactivated state.
5, 22, 23
 Several QSAR studies have been 
performed to enhance the intrinsic potency of dihydropyridine CCB and reduce the side effects 
by designing more potent and selective compounds.
22 
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1.1.5 Pharmacokinetics (PK) of CCB 
Even though the three prototypes of CCB are dissimilar in their chemical scaffold, they 
have similar PK features.
14, 24, 25, 26 
Nifedipine, diltiazem and verapamil have a very good oral 
absorption, as they are almost completely absorbed following oral administration. However, the 
oral bioavailability of these drugs varies because they are subject to various degrees of 
presystemic metabolism by the liver and/or gut, which can lead into pronounced individual 
variation in systemic exposures.
21, 22, 23 
The published oral bioavailability estimates of these 
drugs show that nifedipine has the greatest value (on average 50 to 60%) followed by diltiazem 
(on average 40%) and, finally, verapamil has the lowest value, around 20 to 30%.
24
 Most CCB 
are metabolized in the liver predominately by cytochrome P-450(3A) to inactive or less active 
metabolites.
14, 23
  
CCB have high plasma protein binding with diltiazem being the least plasma protein 
bound (80-85%). Renal clearance of the unchanged (parent) CCB is minimal.
13, 24 
There is a high 
degree of variability in the PK data available about CCB drugs in the literature. For example, 
nifedipine showed high variability when PK data were compared between healthy volunteers 
from Germany and Japan after oral administration of 20 mg.
6
 The same was found for healthy 
Caucasians and Mexicans after using a 10 mg capsule or a 20 mg slow release preparation of 
nifedipine.
6
 However, there are several points that can be mentioned regarding CCB in general: 
Most plasma half-lives of CCB are short, with some exceptions for the newer drugs of the 1,4 
dihydropyridine type: amlodipine (which has the highest half-life), isradipine, nisoldipine and 
nitrendipine.
24
 Oral bioavailability is increased by grapefruit juice for some of CCB which is 
mainly due to inhibition of CYP3A4 in the wall of small intestine.
23
 The effect of grapefruit juice 
is most pronounced for drugs that have a high-first pass metabolism. Therefore, it may increase 
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the bioavailability of these drugs, which will then increase the exposure to the active drugs. In 
fact, the therapeutic index of CCB limits the clinical importance of the interaction with grapefruit, 
but for a few drugs (felodipine, nifedipine, verapamil, and nisoldipine) there is a higher 
interaction.
23
 The volumes of distributions (Vd) of these drugs vary widely from 0.5 
(clevidipine) to 20 L/kg (amlodipine).
 13, 14, 24, 27
 Clevidipine is a vasoselective, ultra short-acting, 
third generation CCB approved in 2008 by the FDA as an intravenous antihypertensive when 
oral therapy cannot be used. This drug is unlikely to be affected by renal or hepatic impairment 
because it is metabolized in the blood and tissue by esterases. Plasma protein bindings of the 
newer agents are very high, and are commonly in excess of 90%. For example, plasma protein 
binding of clevidipine is 99.5%.
 27 
 
1.1.6 Pharmacodynamics (PD) of CCB 
CCB interact with the L-type voltage-gated calcium channels in cell membranes. This 
action leads to different outcomes, which mainly depend on the site of action of these drugs. 
Thus, when these drugs affect the vascular smooth muscle, vasodilation will be seen. However, 
when these drugs affect cardiac muscle, contractility or conductivity of the heart will be 
decreased, and the automaticity in the pacemaker tissues in the heart will be affected.
5, 24 , 28
 The 
dihydropyridine (DHP) group is more selective to vascular muscle, which leads to more 
vasodilatory effects, but only slightly affects AV and SA node conduction (negative inotropic 
effects).
5, 28 
Due to the vasodilatory and hypotensive effects of these drugs, cardiac afterload 
usually decreases and heart rate increases to compensate for DHP-induced negative inotropic 
effects.
5, 28
 Amlodipine and the newer agents in the DHP group are more vasoselective, with 
less negative inotropic effects.
26, 28
 Nimodipine belongs to the dihydropyridine group, but it is 
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more selective for cerebral arteries than systemic arteries. On the other hand, the 
diphenylalkyamine group (verapamil) mainly affects cardiac muscle and thus shows larger 
negative chronotropic, dromotropic and inotropic effects.
14
 Most of the side effects of this 
group are nonvascular in nature because they have little vasodilatory effects and thus cause less 
reflex tachycardia as compared with DHP. Diltiazem affects both vascular and nonvascular 
smooth muscle, demonstrating intermediate vasoselectivity.
15, 6, and 28 
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2 RESEARCH HYPOTHESIS 
 
To assess the relationships of molecular and physicochemical (PC) properties with 
human systemic PK properties for CCB and compare these relationships with other 
pharmacological classes of drugs. 
 
2.1.1 Specific Aims 
 To collect the biologically relevant molecular, PC and human systemic PK properties and 
evaluate their statistical distributions and analyze their collinearity.  
 Evaluate the univariate relationships between PC and PK variables and compare these 
relationships across pharmacological classes of previously studied drugs. 
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3 METHODS 
3.1.1 Definition of biologically relevant PK variables 
The PK variables that were used in this study include: 1) volume of distribution at steady 
state (Vdss); 2) total body clearance (CLtot). 
The term Vdss is used to quantify the distribution of the drugs in the body when every 
compartment in the body that has the drug is at equilibrium. 
29 
This volume of distribution is very 
important because it reflects only the distribution that is not influenced by elimination, thus it is a 
true primary, independent endpoint. However, it is affected by PPB of the drug.
29, 30
 The term fu 
indicates the fraction unbound of drug in plasma, thus it reflects the fraction of drug available for 
distribution, elimination and interaction with the target drug receptors. If fu is low, distribution to 
the tissue may not be extensive and vice versa. In order to achieve an accurate estimation of Vd 
that takes into account the PPB of drugs, Vd has to be divided by fu. Therefore, another term was 
used to correct for PPB, which is abbreviated as Vdss
u 
measures tissue distribution throughout the 
body in absence of PPB. 
29, 30
 
Another PK variable used is CLtot, which is the most important PK property because it 
reflects the efficiency of all eliminating pathways in the body, such as the renal and metabolic 
pathways.
21,  29 , 30
 It is a very useful endpoint for the evaluation of elimination mechanisms, by 
elimination organs such as the kidney and liver. More specifically, renal clearance (CLren) 
represents the clearance of a parent drug and does not account for the metabolites’ renal 
clearance.
29, 30 
 
CLren is a measure of the efficiency of the kidney in removing the drug from the body. 
Furthermore, the value of CLren can indicate the processes by which the kidney removes drugs 
(i.e., glomerular filtration, active tubular secretion, and tubular reabsorption). The term fe is the 
 21 
 
unchanged fraction excreted in urine after administration of the drugs by the IV route. The fe 
values reported after IV administration of the drugs were used to calculate CLren from CLtot as 
shown in Table 3.1. Oral fe was not used in this analysis because it could be misleading if the 
parent compound is not fully absorbed.  
Nonrenal clearance (CLnonren) accounts for all elimination pathways except for CLren 
(CLnonren=CLtot- CLren).
29
 The kidneys and liver are the most important organs for drug 
elimination because they receive large portions of cardiac output; therefore, they are the most 
thoroughly studied.
30
 However, drug elimination through the kidneys is much easier to measure 
than liver clearance. Therefore, CLren is much easier to interpret. Since most of CCB are highly 
lipophilic compounds, it was assumed that CLnonren is equivalent to hepatic metabolism. 
However, it may also be due to CLextrahepatic in blood (clevidipine) and other tissues, such as the 
lungs or brain. In most cases, only the unbound drug is available to the organ for the elimination, 
so it is important to correct for PPB. As a result CLtot
u
, CLren
u
, and CLren
u
 were calculated by 
dividing by fu. Table 3.1 shows the equations that were used to calculate the relevant biological 
PK properties. 
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Table 3.1. Estimation of in-vivo PK variables
29 
PK variables Formula 
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(Assuming two compartment body model) 
     MRTsys = AUMC∞ /AUC∞ (after iv bolus) 
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3.1.2 Definition of PC Variables 
The physicochemical properties (PC) that were used in this analysis are ionization constant 
in water (pKa), molecular weight (MW), molar volume (MV), polar surface area (PSA), 
calculated logP (clogP), percent ionized and calculated clogD at pH 6.3 as well as at pH 7.4. The 
number of hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), and rotatable bonds 
(nRot) were also used. HBA and HBD count the number of bonds between hydrogen 
(electropositive atom) and a strong electronegative atom that might receive a hydrogen bond, 
such as oxygen or nitrogen, respectively.
31, 32
 The number of rotatable bonds is very important 
because it is a measure of molecular flexibility, which is defined as any single, non-ring bound 
on a nonterminal heavy atom (non-hydrogen). Molecular weight and molar volume are used to 
express the size of compounds, but MW is mostly used because it is easier to calculate. PSA is 
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the sum of the surfaces of polar atoms (usually oxygen and nitrogen) and attached hydrogen 
atoms.
32
 The term pKa is used to indicate the ionizability of a compound, which is a function of 
the basicity and/or acidity of the ionizable groups in the compound.
31, 32
 In this analysis, the most 
dominant and basic pKa was used. LogP is the log10 of the partition coefficient, which is used to 
indicate the affinity of a molecule or a moiety for a lipid phase (e.g., biological membranes); it is 
used to measure of lipophilicity of compounds.
31, 32 
Most of the software that were used to 
predict logP have a large database of logP experimental data that help the software build 
relationships between the chemical structures and the values of logP, Then the software will 
predict the logP for the compounds based on the chemical structure of the molecule. In this 
analysis, clogP is predicted using ACD-solubility/DB 12.01 software. The obtained clogP values 
were compared with data obtained from another software, SciFinder Scholar, for the same drugs. 
There were very small differences between the values that were obtained. SciFinder Scholar 
software does not predict logP values; logP value will only appear if it was previously measured 
experimentally. LogP measures the partition coefficient of the molecule in its neutral form, and, 
if more accurate measurement of lipophilicity is required, logD7.4 should be used. Since the 
ionization state depends on the pH of the environment and the pKa of the molecule, lipophilicity 
and solubility will change as the pH changes.
32
 Therefore, logP is not an appropriate measure of 
the molecule’s lipophilicity in the physiological environment of the body. LogD is defined as the 
distribution coefficient between lipid and aqueous phases at different pH values; the most 
relevant pH values of the urine (6.3) and the pH of blood (7.4) to represent the relevant 
physiological pH. 
31, 32
  
 
 
 24 
 
3.2 Data Collection 
3.2.1 Collection of PK variables 
Systemic PK properties were taken from original PK research articles using the following 
specific criteria: Review articles were not used unless the original article was irretrievable. First, 
PK studies were identified when the drug was administered as an IV bolus in healthy volunteers. 
Using intravenous studies ensured that the effects of incomplete absorption or the effects of 
extensive first-pass metabolism did not confound the obtained PK values. 
Healthy volunteers are preferable to avoid any concurrent disease or concomitant drugs 
that may affect the PK properties of drugs. Within each study, study design, dosing regimen, 
sampling schedule, assay procedures and PK analysis methods were evaluated. A study with a 
large number of volunteers is preferable. Generally, the two most important criteria used were 
the values of AUCextra and LLOQ of the bioanalytical assay. In order to have confidence in the 
estimate for the terminal rate constant, a sampling schedule for at least 1-2 terminal half-lives 
should be used. When the contribution of the extrapolated area to the total area under the curve 
(AUCextra/AUC∞), is less than 20%, it is unlikely that there are problems with the sampling time 
schedule. The second criterion is to ensure that all measured plasma concentrations are above the 
lower limit of quantification (LLOQ) of the bioanalytical technique and that any concentration value 
below LLOQ should not be used. Experimental error will be high near the concentration of the 
LLOQ.
33
 In the literature, many articles studied and evaluated the effects of CCB on hepatic and/or 
renal dysfunction population and, in such cases, data from the healthy control population was used 
instead. Also, many studies were focused on the effects of CCB with and without grapefruit juice. 
Under these circumstances, only the control group without the grapefruit was used in this analysis.  
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Body-weight corrected PK properties were calculated using the average body weight 
reported in the study; if the body weight was not reported, a 70 kg body weight was assumed. Vdss 
is the only volume that was used in this analysis; if it was not calculated or reported, two alternative 
approaches were used: For compartmental PK analysis, if the volume of the central compartment 
(Vdcc) and micro-constants or macro-rate constants were calculated and reported in the study, Vdss 
was calculated using the equations in Table 3.1. The other approach was to use published mean or 
individual plasma concentration-time profiles, if they were provided, and to read the values  
electronically (GraphClick version 3.0.2).
33
 Then the values of plasma concentration-time profiles 
were used to calculate the CLtot and Vdss  by non-compartmental analysis using (systemic) mean 
residence time (MRTsys) as shown in Table 3.1. Using the latter approach is less accurate in the 
estimation of Vdss, as usually arithmetic means in the plasma concentration-time plot were provided 
or, in other cases single selected profile was provided preventing assessment of population 
variability.
 28, 33
 In general, the final selected studies were variable in terms of number of subjects, 
doses, sample collection times, techniques and methods of sample analysis and PK analysis 
methods (compartment and noncompartmental). Therefore, arithmetic means of the PK properties 
were calculated across studies for use in the final database used in this analysis. For most of the 
CCB, more than three studies were evaluated (see Appendix I). 
Values for fu in plasma was obtained from in-vitro PPB studies (measured mainly by 
equilibrium dialysis), after critical evaluation of these studies. The incubation time is expected to be 
sufficiently long to reach equilibrium, and fu estimates were corrected for any volume shifts. Also, 
the experimental temperature, drug stability, drug concentration (therapeutic relevant 
concentration), drug stability and ligand stability, plasma source (fresh, frozen, individual donors), 
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and buffer (pH, concentration, composition) were reviewed to ensure that it imitates the 
physiological condition.
34 
To estimate the contribution of renal pathways to the overall elimination pathways, the 
fraction excreted unchanged in urine (fe) was obtained (Table 3.1). The fe was defined as 
accumulative amount excreted unchanged in urine after intravenous administration divided by the 
administered IV dose (bolus or infusion).   .In the final analysis, fe values were obtained from 
studies, where the authors collected the amount of parent drug that was recovered in the urine over a 
sufficient period of time (4-5 t1/2). For several CCB (clevidipine, felodipine, nifedipine, nisoldipine, 
and nitrendipine), urinary excretion was assessed but no parent drug was quantified with the 
bioanalytical method employed. Therefore, fe was set to zero, but CLren was not estimated due to 
imprecision, while CLnonren was estimated as equal to CLtot. 
A summary of PK variables across studies (final values including ± SD for CLtot, and Vd) is 
shown in Appendix I, and the final, individual PK studies are summarized in Appendix II. 
Comparisons between the CCB dose(s) that were used in this study and the therapeutic doses 
were conducted to ensure that each study used therapeutically relevant concentrations. 
Furthermore, the assumption of dose-proportionality or linear PK was verified using the AUC 
estimates at different doses of the CCB. This was done by collecting the values of AUC∞ and 
cmax with each corresponding dose, for each drug from the PK studies that were used in this 
analysis. Then, AUC∞ and/or cmax values were plotted as a function of the corresponding doses. 
These relationships were then evaluated to assess the linearity. A linear relationship was 
concluded if a straight line without an intercept was observed.  CCB were further categorized 
using criteria discussed by Badri (Table 3.2).
21 
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Table 3.2. PK classification of CCB 
 
Classification  Criteria 
Based on plasma protein binding (PPB) 
 
High PPB   fu < 20% 
 
Intermediate PPB  20% < fu < 80% 
 
Low PPB  fu > 80% 
 
Based on the renal clearance 
Net tubular reabsorption CLren
u 
<GFR 
 
Net glomerular filtration CLren
u 
=GFR 
Net tubular secretion CLren
u 
>GFR 
where GFR is the glomerular filtration rate 
(1.7 ml/min/kg) 
 
Table 3.3 Comparison of the therapeutic doses and the PK studies doses for different CCB 
 
CCB   Doses in PK studies    
(µmol/kg) 
Therapeutic Doses            
(µmol/kg) 
Amlodipine  0.17-0.37 0.35 
Bepridil  8.10-10.90 5.45 
Clevidipine  0.001-0.44 0.06-1.00 
Diltiazem  0.58-0.72 0.69-0.86 
Felodipine  0.001-0.1 0.04-0.11 
Fendiline  0.13 0.66-0.92 
Isradipine  0.04-0.07 0.02 
Mibefradil  0.50-2.30 1.00-2.50 
Nicardipine  0.02-0.33 0.02-0.46 
Nifedipine  0.04-0.17 0.21 
Nimodipine  0.04-0.81 0.03-0.07 
Nisoldipine  0.06-0.96 0.01-0.12 
Nitrendipine  0.08-0.19 0.08-0.32 
Verapamil  0.29-0.44 0.16-0.31 
The therapeutic doses in this table were obtained from Micromedex® 2.0 Healthcare Series 
[intranet database]. Version 5.1. Greenwood Village, CO: Thomson Healthcare (2011). 
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3.2.2 Collection of PC variables 
The physicochemical properties (PC) that were used in this analysis were pKa, MW, MV, 
PSA, clogP, HBA, HBD, nRot, percent ionized and clogD at pH 6.3 as well as 7.4. These PC 
properties were chosen after evaluation of a number of studies in the literature providing strong 
evidence that these PC properties may affect the disposition of drugs. The physiochemical 
properties in this study were calculated using ACD-solubility/DB 12.01. The chemical structures 
were drawn for each drug using ChemDraw Ultra 12.0 suite and saved as a mol2 file. Then, the 
saved file was moved to ACD-solubility/DB 12.01 to calculate the PC properties. 
 
3.3 Data Analysis 
3.3.1  Statistical distribution and collinearties 
PK studies for the final fourteen CCB were collected from published literature; the drugs 
were classified according to their chemical structure into four groups; Dihydropyridine (9), 
phenylalkylamine (3), benzothiazepine (1), and benzimidazolyl (1).
 9
 Normal quantile plots were 
used to assess the normality of the mean. If the data for PK and PC were normally distributed, 
the mean and standard deviation were used to describe the central tendency and spread of the 
variable. PK variables (except fu and fe) were log-transformed due to wide dispersion and/or 
skewed distribution. JMP v.10 was used for all statistical computations. 
 
3.3.2 Correlation analysis-PC variables 
Correlation matrices between molecular descriptors were constructed to assess for 
collinearity. Throughout the study, if any two descriptors were found to be collinear (r ≥0.8), 
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then one of them was removed from the univariate analysis based on the relative importance 
biological plausibility of these descriptors. 
 
3.3.3 Correlation analysis-PK variables 
Correlation matrices between PK variables were constructed to assess for collinearity. If 
any two variables were found to be collinear (r ≥0.8), then one of them was removed from the 
univariate analysis based on the importance/biological plausibility of these variables. 
 
3.3.4  Univariate relationships between PK and PC variables 
Univariate linear regression of all PK variables versus each molecular descriptor was 
performed. The criteria that were chosen for a statistically significant relationship were both r
2
 ≥ 
0.3 and p < 0.05. The slopes for all significant relationships were used to evaluate the direction 
and the magnitude of these relationships. These univariate relationships were then compared 
across other classes of drugs: Opioids, β-adrenergic ligands (β-ARLs) and benzodiazepines (BZ) 
that were previously studied.
18
 JMP v10 was used for all statistical analyses. 
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4 RESULTS AND DISCUSSION 
 
4.1.1 Comparison of PC properties   
A total of 14 CCB were included in the final analyses, with 9 of these drugs are classified 
as dihydropyridine CCB. Most CCB drugs used clinically nowadays belong to this group. 
Therefore, CCBs were classified in some textbooks, as dihydropyridine and non-dihydropyridine 
CCB. Overall, CCB are mainly small molecules with molecular weights ranging from 300-500 
Da, which indicates that these drugs are unlikely to have problems with their absorption 
(nonrestricted membrane diffusion) through the GIT membranes, as a consequence of their 
molecular weight.
4
 
Table 4.1 shows the summary and the descriptive statistics of CCB PC properties, and 
Figure 4.1-4.8 shows the distribution of PC properties. Table 4.2 shows the statistical 
interpretation of CCB correlation matrices for the PC properties. Figure 4.8 (B) shows the 
correlation matrices of the CCB PC properties. 
The nRot generally increases with molecular weight, and since molecular weights in this 
dataset are similar (1.6-fold difference across CCB), no major differences in the numbers of 
rotatable bonds of these drugs are expected.
17 
HBA and PSA were found to be highly correlated 
with r ≥ 0.80, and there is a logical explanation behind this correlation: Nitrogen and oxygen 
were used to measure these variables as explained above; therefore, it is expected to have a 
higher correlation between these two molecular descriptors. Thus, PSA was excluded from this 
analysis as a potential predictor variable.
 
There were also two other molecular descriptors (molar 
volume and logD6.3) that were excluded from the analysis as predictors because they were 
correlated with molecular weight and logD7.4, respectively. 
In general, CCBs are mainly basic drugs, which primarily have one pKa that is related to 
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the basic group (-NH group). When the NH group is connected to the aliphatic part of the 
compounds the lone pair on the nitrogen atoms is available for reaction with the protons, and 
therefore the typical pKa values for these compounds (amlodipine, diltiazem and verapamil) are 
between 8 to 9. However, when the NH group is connected to the aromatic ring (pyridine), only 
one electron from the nitrogen contributes to the aromatic ring. This leaves an unshared pair of 
electrons, which can accept a proton, and so this ring is measurably basic, and therefore the 
typical pKa values for these compounds (nifedipine, nimodipine and nisoldipine) are between 2 
and 3.
35 
The pKa value of the compounds relative to the urinary pH may be important in 
determining their renal tubular reabsorption. 
Figure 4.1 indicates that MW has a small range and it is normally distributed. FRB has 
similar mean and median, but it seems to have a bimodal distribution. HBA is skewed to the left 
side, and HBD has a limited range with three outliers, amlodipine is on the high end, and on the 
lower end are verapamil and bepridil. LogP is normally distributed with a very large range 
(1000-fold range in partition coefficient, P). Also, logD7.4 has a large range, and the mean value 
is close to the median value, but the distribution is skewed towards the left. Amlodipine was 
found to be an outlier in logD7.4 (at the low end) and HBD (at the high end). 
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Figure 4.1  Distribution of MW (Da) 
 
 
 
Figure 4.2  Distribution of  nRot 
  
Figure 4.3  Distribution of HBA 
 
Figure 4.4  Distribution of HBD 
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Figure 4.5  Distribution of logP Figure 4.6  Distribution of molar volume 
(cm3/mol) 
 
 
 
  
Figure 4.7  Distribution of logD7.4 Figure 4.8  Distribution of PSA 
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Table 4.1 Summary of physicochemical properties of CCB  
Drug MW CCB 
classification 
nRot HBA HBD clogP Molar 
Volume, 
(cm
3
/mol) 
pKa logD6.3 logD7.4 
 
%Ionized 
@pH 6.3 
%Ionized 
@pH 7.4 
PSA 
(A
2
) 
Amlodipine 409 Dihydropyridine 11 7 3 3.0 333 9.0 0.52 1.5 100 97 100 
Bepridil 367 Phenylalkylamine 10 3 0 5.4 348 9.2 2.78 3.7 100 98 16 
Clevidipine 456 Dihydropyridine 10 7 1 5.1 354 2.5 5.11 5.1 100 100 91 
Diltiazem 415 Benzothiazepine 7 5 1 3.4 328 8.9 2.36 3.4 100 96 84 
Felodipine 384 Dihydropyridine 6 5 1 4.8 301 2.7 4.76 4.8 100 100 65 
Fendiline 315 Phenylalkylamine 7 1 1 5.2 306 9.5 2.36 3.2 100 99 12 
Isradipine 371 Dihydropyridine 6 8 1 3.7 297 2.6 3.73 3.7 100 100 104 
Mibefradil 496 Benzimidazolyl 12 6 1 6.2 418 11.9 3.32 4.3 100 99 67 
Nicardipine 480 Dihydropyridine 11 9 1 4.9 390 7.3 3.85 4.6 91 45 114 
Nifedipine 346 Dihydropyridine 6 8 1 3.6 272 2.7 3.58 3.6 100 100 111 
Nimodipine 418 Dihydropyridine 10 9 1 4.1 345 2.8 4.05 4.1 100 100 120 
Nisoldipine 388 Dihydropyridine 8 8 1 5.0 322 2.7 4.95 5.0 100 100 111 
Nitrendipine 360 Dihydropyridine 7 8 1 3.8 289 2.8 3.81 3.8 100 100 111 
Verapamil 455 Phenylalkylamine 13 6 0 4.0 429 9.0 1.49 2.5 100 97 64 
25%
*
  364  6.8 5 1 3.7 300 2.7 2.40 3.3 100 97 65 
Mean 404.3  9 6 1 4.4 338 6.0 3.33 3.8 99 95 83 
75%
* 
455  11 8 1 5.1 362 9.0 4.20 4.7 100 100 111 
SD 52.5  2 2 1 0.9 47 3.5 1.32 1.0 2 15 35 
COV 13%  27% 36% 68% 21% 14% 59% 40% 26% 2% 15% 42% 
Minimum 315.5  6 1 0 3.0 272 2.5 0.52 1.5 91 45 12 
Maximum 495.6  13 9 3 6.2 429 11.9 5.11 5.1 100 100 120 
Fold range 1.6  2.2 9.0 4 2.1 1.6 4.9 9.80 3.4 1 2 10 
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Drug MW CCB 
classification 
nRot HBA HBD clogP Molar 
Volume, 
(cm
3
/mol) 
pKa logD6.3 logD7.4 
 
%Ionized 
@pH 6.3 
%Ionized 
@pH 7.4 
PSA 
(A
2
) 
Difference 180.2  7.0 8.0 3.0 3.2 157 9.5 4.59 3.6 9 55  108 
n 14  14 14 14 14 14 14 14 14 14 14 14 
*25%: 25 percentile, *75%: 75 percentile.  
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Figure 4.8 (B) Correlation matrices of PC variables  
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Table 4.2 Statistical interpretations of PC variables correlation matrices   
 
MW    nRot HBA HBD clogP MV logD7.4 PSA  
MW    1.00        
nRot 0.76 1.00       
HBA 0.37 0.09 1.00      
HBD -0.01 -0.05 0.25 1.00     
clogP 0.27 0.28 -0.36 -0.42 1.00    
MV 0.85 0.92 0.02 -0.27 0.42 1.00   
logD7.4 0.20 -0.21 0.24 -0.36 0.59 -0.03 1.00  
PSA  0.26 -0.07 0.96 0.39 -0.50 -0.15 0.19 1.00 
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4.1.2 Comparison of PK properties   
 
Table 4.4 shows the final PK properties and their descriptive statistics for this dataset, 
and Figure 4.17(B) shows the correlation matrices of the CCB PK properties. Table 4.4 shows 
the statistical interpretation of CCB correlation matrices for the PK properties. Figures 4.9-4.16 
show the distribution of various PK properties. 
In the final dataset, there was a higher dispersion in the PK variables than the PC 
variables, which is clearly shown by a high standard deviation and the skewed distributions of 
these variables. Therefore, for the remainder of the analysis, the PK variables were log-
transformed except for fu. 
The fu values for most of the compounds were very low (less than 0.03%), and the fu 
values were normally distributed. Two outliers (diltiazem and verapamil) had high fu values. 
In general, CCB exhibit somewhat similar PK properties, despite their differences in 
chemical structure and pharmacological activity: CCB are almost completely absorbed from the 
GIT, but they suffer from various degrees of first-pass metabolism, and, as a consequence, their 
oral bioavailability can be low, with wide inter and intra-patient variability (except amlodipine). 
Mainly inactive metabolites are formed after hepatic metabolism, with the exception of 
clevidipine. Clevidipine was found to be an outlier in CLtot, CLtot
u
, CLnonren, and CLnonren
u
 due to 
the presence of an additional ester group on the molecule, as the compound is rapidly 
metabolized by esterases in blood and extravascular tissues into the corresponding carboxylic 
acid metabolite.
27 
Renal elimination of the unchanged CCB is very low, thus CLren is a negligible 
route of CCB elimination.
 29, 31, 32
 Although there are studies in the literature that try to measure 
the parent drug concentrations in urine, for most of the compounds they were not able to detect 
it. Since most of these studies did not report the LLOQ, it was difficult to come up with estimates 
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of CLren values, and as a result only four values for CLren were estimated in this analysis.  
The mean Vdss value in this dataset is 5.3 l/kg, which indicates that these drugs leave the 
vascular space and are highly distributed into body tissues. Amlodipine, with the highest value 
for Vdss of 20 l/kg, was found to be an outlier. After correction of PPB, bepridil was found to be 
an outlier with the highest value for Vdss
u
. 
The values for CLnonren values in this dataset range between 7-131.5 ml/min/kg - with a 
mean value of 25.4 ml/min/kg, indicating that CCB have a moderate to high hepatic extraction 
ratio. Amlodipine is the only drug in this dataset that has a low extraction ratio. Most if not all, of 
CLnonren is attributable to hepatic metabolism except for clevidipine (see above). As discussed 
before, hepatic metabolism results in the formation of inactive/less active metabolites primarily 
due to oxidation by cytochrome P-450(3A); ester hydrolysis (except for clevidipine) is thought to 
be a minor pathway of hepatic metabolism.
4, 14, 27 
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Figure 4.9 Distribution of CLtot  (n=14) 
 
 
 
 
Figure 4.10 Distribution of Vdss (n=14) 
  
Figure 4.11 Distribution of fu (n=13) 
 
Figure 4.12 Distribution of CLren (n=4) 
 
  
 41 
 
  
Figure 4.13 Distribution of CLnonren (n=9) 
 
 
 
Figure 4.14 Distribution of Vdss
u 
(n=13) 
  
Figure 4.15 Distribution of CLtot
u
 (n=13) 
 
 
 
Figure 4.16 Distribution of CLnonren
u 
(n=9) 
 
 
Figure 4.17 Distribution of CLren
u 
(n=4) 
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Table 4.3 Summary of the PK variables of CCB 
Drug CLtot 
[ml/min/kg] 
Vdss 
[l/kg] 
fe  
[%] 
CLren 
[ml/min/kg] 
CLnonren 
[ml/min/kg] 
fu [%] CLtot
u
 
[ml/min/kg] 
CLnonren
u
 
[ml/min/kg] 
CLren
u
 
[ml/min/kg] 
Vdss
u
 
[l/kg] 
Amlodipine 6.9 20.4 4.00% 0.278 6.7 2.0% 347 333 13.9 1022 
Bepridil 8.7 10.1    0.2% 3783   4391 
Clevidipine 131.5 0.57 0.00%  131.5 0.3% 41094 41093  178 
Diltiazem 10.9 2.7 6.60% 0.717 10.2 20.0% 54 51 3.6 14 
Felodipine 11.9 8.1 0.00%  11.9 0.4% 3389 3389  2300 
Fendiline 17.4 13.8         
Isradipine 12.3 1.0    2.5% 492   42 
Mibefradil 3.7 2.8    0.4% 925   700 
Nicardipine 10.6 0.7 0.03% 0.003 10.6 1.1% 978 978 0.3 66 
Nifedipine 7.4 0.7 0.00%  7.4 4.3% 175 175  16 
Nimodipine 16.4 1.5    2.0% 822   74 
Nisoldipine 11.3 3.6 0.00%  11.3 0.3% 3767 3767  1193 
Nitrendipine 25.0 4.8 0.00%  25.0 2.2% 1125 1125  218 
Verapamil 15.1 4.0 3.90% 0.587 14.5 10.0% 151 145 5.9 40 
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25%
* 
8.4 1.0 0% 0.07 8.8 0.23% 261 160 1.1 41 
Mean 20.6 5.3 1.6% 0.396 25.4 3.5% 4392 5673 5.9 789 
75%
* 
16.7 11.8 3.95% 0.6 19.7 3.3% 3577 3578 11.8 1107 
SD 32.3 5.9 2.5% 0.321 40.1 5.6% 10742 13356 5.8 1244 
COV 157% 110% 157% 81% 158% 160% 245% 235% 98% 158% 
Minimum 3.7 0.6 0.00% 0.003 6.7 0.2% 54 51 0.3 14 
Maximum 131.5 20.4 6.6% 0.717 131.5 20.0% 41094 41093 13.9 4391 
Fold range 35.5 35.8   251.6 19.7 100.0 756.1 809.5 52.6 324.1 
Difference 127.8 19.9 6.60 0.715 124.8 19.8% 41039 41042 13.6 4378 
n 14 14 9 4 9 13 13 9 4 13 
*25%: 25 percentile, *75%: 75 percentile.  
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Figure 4.17 (B)  Correlation matrices of PK variables 
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Table 4.4 Statistical interpretation of CCB PK variables correlation matrices   
 CLtot Vdss CLren CLnonren fu CLtot
u
 CLnonren
u
 CLren
u
 Vdss
u
 
CLtot 1.00         
Vdss -0.24 1.00        
CLren 0.43 -0.12 1.00       
CLnonren 1.00 -0.30 0.35 1.00      
fu -0.16 -0.14 0.91 -0.25 1.00     
CLtot
u
 0.98 -0.20 -0.95 0.99 -0.23 1.00     
CLnonren
u
 0.99 -0.27 -0.95 0.99 -0.29 1.00 1.00    
CLren
u
 -0.51 0.97 0.09 -0.54 -0.24 -0.40 -0.41 1.00   
Vdss
u
 -0.18 0.51 -0.29 -0.20 -0.35 -0.04 -0.10 0.91 1.00 
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CCBs varied in their total body clearance from 3.7 (mibefradil) to 131.5 
ml/min/kg (clevidipine). The clevidipine clearance value is an outlier within this dataset, 
as it is the highest value exceeding liver blood flow (LBF) and cardiac output due to 
extrahepatic tissue and blood hydrolysis (see above).
27
 As a result, clevidipine has the 
shortest t1/2, which makes it unique among the other DHP CCB. Clevidipine also has a 
greater vasoselectivity with an ultra-short half-life that is required when rapid and 
controlled reduction of blood pressure is necessary.
27
 Clevidipine is used as an 
intravenous antihypertensive agent because it is easily titratable with a low risk for 
toxicity and drug-drug interactions.
27 
Overall, CCB were found to be highly metabolized, and their CLnonren values 
approached or exceeded LBF (20 ml/min/kg), indicating that they have a moderate to 
high hepatic extraction ratio (ERhep), except for amlodipine. Since CCB are highly 
lipophilic drugs, CLnonren in this dataset was assumed to be due to hepatic elimination, 
which means that CLnonren represents CLhep, except for clevidipine. 
Smith et al.
40
 studied the in-vitro hepatic metabolism of dihydropyridine CCB and 
found that these compounds are essentially converted to the pyridine metabolites (human 
and animals) as the common, initial clearance step. He reported the intrinsic clearance 
(CLint in ml/min/kg) of 6 dihydropyridine CCB, namely amlodipine (11), nitrendipine 
(88), felodipine (75), nicardipine (131), nisoldipine (190), and nilvadipine (100). The 
intrinsic clearance is defined as the intrinsic ability of liver to remove a drug in the liver 
in absence of flow limitations. These values clearly indicate that the liver efficiently 
clears these drugs, but because they are highly plasma protein bound (binding-restricted 
drugs), only moderate ERhep can be seen for some of these drugs. The CLnonren
u
 values 
 47 
 
calculated using the current dataset of CCB were much higher than the previously 
reported estimates of CLint (see table 4.5). After correction for PPB, it was observed that 
the values of CLnonren
u
 exceeded the liver blood flow for all the drugs in this dataset. 
However, when Smith et al
40
 estimated CLint based on studies which were conducted in 
different animals species (rat, dog and monkey) from literature and extrapolated to 
human CLint. However, the model used for the estimation was not described in the study. 
Furthermore, the methods of estimation of CLint, and the assumptions underlying each of 
studies - Smith et al.
40
 and this study - could be potential explanations for the 
discrepancies in the estimates of CLint values of CCB from these studies. An additional 
explanation would be that each study used different PPB estimates; since it is a very 
small value, the final results for CLint could change significantly. However, the values 
from both studies clearly indicate that these CCB are highly metabolized. 
Table 4.5. Comparison between CLint from Smith et al.
40
 and CLnon
u
  from the 
current study 
CCB CLint 
(ml/min/kg)
40 
CLnonren
u 
(ml/min/kg) 
Amlodipine 11 333 
Felodipine 75 3388 
Nicardipine 131 977 
Nisoldipine 190 3766 
Nitrendipine 88 1124 
 
Waterbeemed et al.
35
, studied the correlation between the CLint as a function of 
logD7.4 for nine CCB, but did not perform any regression analysis on this relationship 
(CLint  was obtained by in-vitro-in-vivo-extrapolation). These published data were read 
electronically (GraphClick version 3.0.2), and linear regression was performed on the 
log-transformed values of CLint as function of log D7.4 to obtain the slope (S = 0.58) and 
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regression coefficient (r
2 
= 0.77, n=9) shown in Figure 4.17C. Results obtained from the 
current QSPKR study (n = 9, S = 0.56, r
2
 = 0.42) indicated similar direction and 
magnitude of the trend (slope). This suggests that the effect of lipophilicity on 
hepatic/nonrenal clearance of CCB is very consistent across both studies.  
 
 
Figure 4.17(C) Univariate relationship of log-transformed CLint as a function of  
logD7.4 using data from Waterbeemed et al.
35
, 
 
Renal clearance typically decreases with increased in lipophilicity because 
compounds that have a higher lipophilicity, like CCB, should have a higher passive 
permeability (tubular reabsorption).
36
 Another reason why renal clearance is low for these 
drugs is the high PPB (>80%), which means that these drugs will be less available for 
glomerular filtration.
36
 The contribution of CLren  to CLtot is negligible because the renal 
clearance of these drugs is less important compared to CLnonren, and because it is difficult 
to find studies that allow valid estimates on CLren of CCB after IV administration. In fact, 
when these studies were found, most of them did not have detailed information. For 
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example, Raemsch et al.
37
 studied the metabolism and excretion of intravenous 
nimodipine and mentioned that “no unchanged drug was found in the urine during the 
first 24 hours (>10 t1/2)”, but the lower limit of quantification (LLOQ) of this study was 
not mentioned. Under these circumstances, it could be that there is no parent drug 
excreted in the urine, or there is a small percent of the parent drug excreted in the urine 
and the bioanalytical technique is not able to detect it. The only way to differentiate 
between the two cases is by knowing the LLOQ of the assay that was used. For this 
reason, nine values of CLren are missing in this analysis. However, the value of CLren is 
very small compared to the value of CLnonren, so it possible to use these studies to 
estimates the CLnonren. 
CCB varied in their CLren
u
 values from 0.3 (nicardipine) to 13.9 ml/min/kg 
(amlodipine), which in the case of nicardipine CLren
u
 is less than glomerular filtration rate 
(GFR), indicating that it undergoes net tubular reabsorption. However, on the other hand, 
amlodipine exceeds GFR, indicating that it undergoes net tubular secretion.
41
 
The volume of distribution of these drugs is high; most of the values 
(approximately 85%) exceed the total body water. Clevidipine shows the lowest Vdss (0.6 
l/kg), while amlodipine shows the highest Vdss (20.4 L/kg). This would indicate that most 
of these compounds are extensively distributed into body tissues. The distribution of the 
drugs in the body is mainly dependent on the lipophilicity, which is expressed by logD7.4, 
and PPB. In fact, PPB for most of CCB is very high, exceeding 90% except for diltiazem 
(80%). Therefore, free (unbound) drugs that are available to produce the pharmacological 
action are very limited. 
Furthermore, PPB is also important in terms of drug disposition, which influences 
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the Vdss and the total clearance of these drugs. After correction of PPB, it was observed 
that the Vdss
u
 exceeds total body water volume or total body weight, indicating extensive 
distribution in to the body tissues. 
CLren values for CCB are below GFR, but would have to be corrected for PPB; 
CLren
u
 values become higher than GFR for amlodipine, diltiazem and verapamil, which 
suggest net tubular secretion. The theoretical concepts of the relationships between PPB 
and renal clearance of drugs are well defined and are consistent with our finding between 
renal clearance and fu.
36
 As fu increased, renal clearance increased (r
2
=0.91). There was a 
higher correlation between CLtot and CLnonren (r
2
=1.0), which suggests that the non-renal 
pathway is mainly responsible for the total clearance of these drugs and the renal 
clearance pathway is very small. 
 
4.1.3   QSPKR 
The results of the univariate regression between PK and PC for the complete 
dataset, with and without amlodipine, are shown in Table 4.6 and Table 4.7, respectively. 
Amlodipine was separated out because it was an outlier in one of the PC and one of the 
PK properties, and because it had different PK properties compared to the other CCB.  
The question remains of why amlodipine is different compared to other CCB. 
Amlodipine has the largest plasma half-life across all CCB, and good oral bioavailability 
(60 to 65%) because it has lower presystemic or first-pass metabolism.
41
 Oral CCB have 
good absorption characteristics, as discussed before, but metabolic enzymes inactivate a 
large fraction of these drugs and reduce their oral bioavailability. Therefore, the CCB that 
is subjected to first-pass metabolism requires a large dose to be administered to ensure 
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that an effective concentration of active drug exits the liver and reaches the systemic 
circulation; otherwise, it will not be available in the site of action. Clinically, amlodipine 
is administered in a smaller dose than other CCB because it is not subjected to a large 
first-pass metabolism.
42, 43
 Amlodipine is a basic drug with a pKa of 8.97, which means 
that, at physiological pH, it is mainly ionized (positively charged). This positive charge of 
the amino group (pKa is 8.7) allows this drug to bind with a high affinity to cell 
membranes in peripheral body tissue that are mainly negatively charged.
42 
Therfore, 
despite its large PPB, amlodipine has the largest Vdss (21 L/kg) across all CCB.
42, 43
 
Amlodipine has a PK profile that is unlike any of the other CCB available in the market 
or present in this study. It. 
 
For all of the above reasons, the analysis was performed with 
and without amlodipine.  
In this analysis, there was no single PC variable showing a high relationship such 
that a single PC property could be used alone to predict a human PK property; however, 
there were trends, suggesting a significant contribution of some PC properties to certain 
human PK properties. After critical evaluation of several published studies, only 
particular PC properties were prespecified earlier in this analysis.
15, 16, 17
 These PC 
properties that found to affect the biologically relevant, systemic PK properties were 
chosen. PC properties that affect the drugs after giving by oral route were not used in this 
analysis. 
Figures 4.18-4.26 shows the univariate relationships between PC vs. logD7.4 for 
the complete set and Figures 4.27-4.35 for the reduced set without amlodipine.There is a 
significant negative relationship between lipophilicity measured by logD7.4 and fu (Figure 
4.23). This finding is consistent with other classes of drugs such as opioids, 
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benzodiazepines, β-blockers and anti-arrhythmic drugs in humans.21, 44,45 Waterbeemd et 
al.
35
 studied this relationship between plasma protein binding and lipophilicity (logD7.4) 
of 150 acidic, basic, and neutral compounds. He found a sigmoidal relation between fu 
and logD7.4 and this relationship became linear after transformation of the data to a 
logarithmic form. He also observed that basic compounds that have logD7.4 >2 will have 
lower fu. Obach et al.
14
 also studied the same relationships with a larger number of 
compounds (554) and found a trend in the data in that drugs with a higher logD7.4 had a 
higher PPB. Basic compounds like CCB are expected to bind to 1-acid glycoprotein due 
to an electrostatic interaction with acidic residues.
30 
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Figure 4.18 CLtot vs. log D7.4 Figure 4.19 Vdss vs. log D7.4 
  
      Figure 4.20 CLnonren vs. log D7.4       Figure 4.21 CLren vs. log D7.4 
  
            Figure 4.22 fu vs. log D7.4      Figure 4.23 CLtot
u
 vs. log D7.4 
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Figure 4.24 CLnon m  
u 
vs. logD7.4 Figure 4.25 CLren
u
 vs. logD7.4 
 
            Figure 4.26 Vdss
u
 vs. logD7.4 
 
 
There were no significant relationships between Vdss, Vdss
u
 and logD7.4, which is 
inconsistent with several references.
15, 17 
Waterbeemd et al.
35
 studied the relationship 
between the unbound volume of distribution and logD7.4 and found a strong relationship. 
To understand more about this relationship, we have to identify other factors that can 
affect the volume of distribution. A major factor that affects the Vdss is the affinity for the 
cell membranes in peripheral tissues. The two physiochemical properties that impact this 
affinity are the compound’s basicity and its intrinsic lipophilicity. 15, 17 In the case of 
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CCB, they are basic drugs fully ionized at physiological pH; thus, there is an ion-pair 
interaction between the charged acidic groups of the membranes and the basic center of 
the drug. To separate the effects of ionization from the intrinsic lipophilicity, pKa values 
were divided in this dataset and used the part of the data that have similar pKa values. 
This relationship between logD7.4 on the drugs that has similar pKa (7.3-9.8) and Vdss was 
studied. It was found that r
2 
increased from 0.08 to 0.53 (p-value= 0.06, n=6). Although 
this relationship is still not statistically significant and has a small sample size, an 
improvement in this relationship with the expected trend was seen. It may have required a 
larger sample size to show a statistically significant relationship especially for basic drugs 
that are fully ionized at physiological pH. On the other hand, a significant relationship 
between logP and Vdss
u
 was found (r
2
=0.54, n=12); logP depends on the partitioning of 
the neutral molecules between the aqueous phase and the organic phase.
47 
 
  
Figure  4.27 CLtot vs. logD7.4 (without 
amlodipine) 
 
Figure 4.28 Vdss vs. logD7.4 (without 
amlodipine) 
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Figure 4.29 CLnonren vs. logD7.4(without 
amlodipine) 
Figure 4.30 CLren vs. logD7.4(without 
amlodipine) 
 
 
  
Figure 4.31 fu vs. logD7.4(without 
amlodipine) 
 
Figure 4.32 CLtot
u
 vs. logD7.4(without 
amlodipine) 
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Figure 4.33 CLnonren
u
 vs. logD7.4 
(without amlodipine) 
 
Figure 4.34 CLren
u
 vs. logD7.4 (without 
amlodipine) 
 
 
   Figure 4.35 Vdss
u
 vs. logD7.4 (without amlodipine) 
 
Generally, most CCB in this dataset are highly lipophilic, hepatically metabolized 
compounds.
25, 6 
Thus, CLnonren
 
primarily represents their hepatic intrinsic clearance and 
PPB. CLtot
u
 and CLnonren
u
 showed a strong relationship with logD7.4; as logD7.4 increased, 
CLtot
u
 and CLnonren
u
 increased. CCB have very low renal clearance, and, if these drugs 
have low or negligible renal clearances, they are most likely to be dependent on hepatic 
metabolism for clearance.
47
 Smith et al.
48
 has studied the relationship for a series of 
compounds and found that, where increasing logD7.4 above zero shows a significant 
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reduction in CLren; however, increasing lipophilicity results in higher metabolic 
clearance. For CCB, the expected trend was found between logD7.4 and renal clearance, 
but it was not significant which may have been due to small sample size.  
Lipophilicity is an important property in governing binding of drugs to the active 
site of many enzymes of drug metabolism and also portioning into the liver. Thus, while 
increasing lipophilicity (logD7.4) above zero will reduce renal clearance, it may increase 
metabolic clearance. Therefore, there were two opposing effects; unbound renal clearance 
decreasing with logD7.4 and CLnonren
u
 increasing with log D7.4. The two main factors that 
affect the CLnonren are PPB and/or intrinsic clearance.
17
 There was a significant negative 
relationship between log D7.4 and fu, and there were no significant relationships between 
log D7.4 and both CLnonren and CLtot, but these relationships became significant after 
correcting of plasma protein binding. As discussed before logD7.4 was found to lead to 
increase hepatic CLint (smith et al.
40
).which explains the relationship for CLnonren
u
. 
Overall, the decrease in fu with logD7.4, is therefore offset by the increase in CLint leading 
to a lack of effects on CLnonren. 
Table 4.8 shows a comparison of the univariate effects of logD7.4 on the human 
PK variables for opioids
21, β-ARLs21, benzodiazepines45 and CCB (without amlodipine): 
LogD7.4 was found to be the most important molecular property to be associated 
with biological relevant PK properties when compared to the three groups, versus logD7.4 
especially for lipophilic compounds like β-ARLs and opioids.21 However, the slope of fu 
is shallower for CCB, but it still has the same, expected direction as the other drug 
classes. When logD7.4 increases, fu decreases, however, the slope is slower here compared 
to other groups because the number of compounds that was used in this study is lower 
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than the other groups and because there were two outliers (diltiazem and verapamil) in fu. 
Another important reason is that CCB are highly PPB, and the fraction unbound in 
plasma is very low in most of these compounds. In fact, the mean values of fu are 3.5%, 
47%, and 53% for CCB, opioids, and β-ARLs respectively.21 Finally, CCB have the 
lowest range in logD7.4 compared to the other drug classes.
 
The relationship between CLtot
u
 and logD7.4 has a much steeper slope for CCB 
compared to the other drug classes. The values of logD7.4 indicate that most of the CCB in 
this dataset are highly lipophilic drugs while in the other groups both hydrophilic and 
lipophilic drugs are included. Therefore, the slopes obtained in the univariate log-linear 
regression between CLtot
u
 and logD7.4 is steeper for CCB than those obtained for the other 
three groups. After correcting for renal clearance, to focus on metabolic clearance, better 
sensitivity can be seen between CLtot
u
 and logD7.4 compared with CLtot
u
; the 
slope/sensitivity values also become more consistent with the other drug classes. A 
possible explanation for this finding is that, because CCB are mainly metabolized by 
cytochrome P-450(3A) in the liver and since CCB have an average, higher logD7.4 values, 
they become more vulnerable to cytochrome P-450(3A) metabolism, thus leading to a 
higher hepatic clearance .
23, 24
 There is a positive relationship between logD7.4 and CLint, 
and hence these compounds are mainly eliminated by metabolism so they are very 
sensitive to any change in logD7.4. On the other hand, in the other drug classes, like β-
ARLs, there are some drugs, such as atenolol and sotalol, which are mainly cleared by the 
renal pathways, and many factors besides logD7.4 may affect their overall elimination.
36
 
Univariate analysis showed a significant effect of HBA, clogP and logD7.4 on 
certain human PK properties. However, logD7.4 ranges from 1.5 to 5, was the most 
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important molecular property, and affected most of the biological relevant PK properties 
for CCB. The slopes for all PK variables vs. log logD7.4 remained similar among the 
dataset with and without amlodipine, thus demonstrating that the effect of PC on these 
variables was similar. However, exclusion of amlodipine lead to improvement in r
2
, and a 
decrease in p-value, conforming that amlodipine is a PK outlier, whose Vdss and fu.in 
particular, do not follow the trend of logD7.4. 
There were a number of limitations in this study: the first limitation was that the 
studies used to obtain the PK values did not have the same study design. The studies 
varied from drug to drug with regard to administered dose, blood sampling times, 
bioanalytical techniques, the number of subjects, etc. The second limitation was that the 
PK values reported were mean values and did not account for inter-subject variability. 
Furthermore, CLren for most of the compounds was poorly estimated and/or not available 
since most of the compounds are eliminated by nonrenal pathways. A further limitation 
was that the final sample size of CCB used in this study was relatively small, and, more 
importantly, the sample was limited to drugs that made it through the drug development 
to clinical use.  Thus, the final database is representative of the clinically used CCB, but 
not covering a large range of PC properties (other than logD7.4), as would have been 
desirable in order to establish generalizable QSPKR.  In addition, the non-
dihydropyridine class of CCB contained only a limited number of compounds, which 
made it difficult to compare within the dihydropyridine group. Finally, due to the small 
sample size and limited diversity in PC variables (except logD7.4) only linear, univariate 
relationships were explored, other nonlinear models and/or interactions between more 
than one PC variable were not studied. 
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4.1.4 Overall conclusions 
CCB in the final dataset (n=14) are – based on their PC characteristics - a fairly 
homogeneous, but clinically representative group of compounds that are highly lipophilic 
(logD7.4>3) for most of the compounds except amlodipine (logD7.4 =1.5), which makes 
them more vulnerable to hepatic cytochrome P-450(3A) metabolism, leading to high 
hepatic/nonrenal clearance, while fu and CLren are low. The final QSPKR obtained in this 
study showed significant and plausible relationships between biological relevant PK 
properties and logD7.4; the observed effects were consistent with other classes of drugs 
previously studied, i.e., opioids, β-ARL and benzodiazepines. However, slope estimates 
for the relationships of CLnonren
u 
and CLtot
u 
as a function of logD7.4 for CCB were higher 
compared to these other compounds, most likely as a result of the higher average 
lipophilicity of CCB. However, amlodipine proved to be an outlier based on its high 
HBD (3), lowest logD7.4 (1.5) value, which despite the overall trends, led to the highest 
Vdss (20 l/kg), the second lowest CLtot value (6.9 ml/min/kg) and relatively high PPB 
(fu=2%).  This reflects presumably the effects of increased basicity of the amlodipine 
molecule, not captured in the PC variables. Better understanding of the PK and PD 
properties of amlodipine may make an important contribution to the discovery of new 
drugs or the development of the existing CCB. 
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Table 4.6  Regressions between PC and PK Variables (all CCB) 
 fu log (Vdss ) log  (CLtot) log (CLren) log (CLnonren) log (CLtot
u
) log (CLren
u
) log (CLnonren
u
) Log (Vdss
u
) 
MW n=13 
r
2
<0.001 
Slope 
<0.001 
(N.S.) 
n=14 
r
2
=0.12 
Slope = 
-0.003 
(N.S.) 
n=14 
r
2
= <0.001 
slope< 
-0.001 
(N.S.) 
n= 4 
r
2
= 0.56 
slope= 
-0.025 
(N.S.) 
n=9 
r
2
=0.08 
slope= 
0.002 
(N.S.) 
n=13 
r
2
<0.001 
slope 
<0.001 
(N.S.) 
n=4 
r
2
=0.64 
slope= 
-0.018 
(N.S.) 
n=9 
r
2
=0.023 
slope= 0.004 
(N.S.) 
n=13 
r
2
=0.006 
slope= 
-0.001 
(N.S.) 
logD7.4  n=13 
r
2
=0.15 
Slope = 
-0.02 
(N.S.) 
n=14 
r
2
=0.25 
slope= 
-0.25 
(N.S.) 
n=14 
r
2
=0.06 
slope= 
0.12 
(N.S.) 
n=4 
r
2
=0.52 
slope= 
-0.615 
(N.S.) 
n=9 
r
2
=0.24 
slope= 
0.15 
(N.S.) 
n=13 
r
2
=0.36 
slope= 
0.53 
(p=0.03) 
n=4 
r
2
=0.89 
slope= 
-0.52 
(p=0.053) 
n=9 
r
2
=0.42 
slope= 
0.56 
(p=0.057) 
n=13 
r
2
=0.03 
slope= 
0.14 
(N.S.) 
nRot n=13 
r
2
=0.01 
slope= 
-0.002 
n=14 
r
2
=0.00 
slope= 
0.01 
n=14 
r
2
=0.01 
slope= 
-0.012 
n=4 
r
2
=0.03 
slope= 
-0.085 
n=9 
r
2
=0.01 
slope= 
0.019 
n=13 
r
2
<0.001 
slope= 
<0.001 
n=4 
r
2
<0.001 
slope= 
0.007 
n=9 
r
2
=0.001 
slope= 
-0.015 
n=13 
r
2
=0.02 
slope= 
0.05 
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(N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
HBA n=13 
r
2
=0.06 
slope= 
-0.007 
(N.S.) 
n=14 
r
2
=0.37 
Slope = 
-0.131 
P(0.02) 
n=14 
r
2
=0.01 
Slope 
=0.0146 
(N.S.) 
n=4 
r
2
=0.88 
Slope = 
-0.622 
p(0.06) 
n=9 
r
2
=0 
Slope = 
0 
(N.S.) 
n=13 
r
2
=0.02 
Slope = 
-0.07 
(N.S.) 
n=4 
r
2
=0.5 
Slope = 
-0.31 
(N.S.) 
n=9 
r
2
=0.007 
Slope = 
0.0625 
(N.S.) 
n=13 
r
2
=0.19 
Slope = 
-0.202 
(N.S.) 
HBD n=13 
r
2
=0.02 
Slope = 
-0.010 
(N.S.) 
n=14 
r
2
=0.05 
Slope = 
0.16 
(N.S.) 
n=14 
r
2
=0.03 
Slope = 
-0.08 
(N.S.) 
n=4 
r
2
<0.001 
Slope = 
-0.002 
(N.S.) 
n=9 
r
2
=0.1 
Slope = 
-0.15 
(N.S.) 
n=13 
r
2
=<0.001 
Slope = 
<-0.001 
(N.S.) 
n=4 
r
2
=0.11 
Slope = 
0.19 
(N.S.) 
n=9 
r
2
=0.02 
Slope = 
0.181 
(N.S.) 
n=13 
r
2
=0.012 
Slope = 
0.13 
(N.S.) 
clogP n=13 
r
2
=0.25 
Slope = 
-0.03 
(0.08) 
n=14 
r
2
<0.01 
Slope = 
0.006 
(N.S.) 
n=14 
r
2
<0.001 
Slope = 
0.005 
(N.S.) 
n=4 
r2=0.64 
Slope = 
-1.09 
(N.S.) 
n=9 
r
2
=0.28 
Slope = 
0.26 
(N.S.) 
n=13 
r
2
=0.32 
Slope = 
0.55 
(0.04) 
n=4 
r
2
=0.7 
Slope = 
-0.809 
(N.S.) 
n=9 
r
2
=0.53 
Slope = 
0.99 
(0.025) 
n=13 
r
2
=0.27 
Slope = 
0.47 
(N.S.) 
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Table 4.7  Regressions between PC and PK Variables without Amlodipine 
 fu log (Vdss) log  (CLtot) log (CLren) log (CLnonren) log (CLtot
u
) log (CLren
u
) log (CLnonren
u
) log (Vdss
u
) 
MW n=12 
r
2
<0.001 
slope< 
0.001 
(N.S.) 
n=13 
r
2
=0.18 
slope =  
-0.003 
(N.S.) 
n=13 
r
2
 <0.001 
slope< 
-0.001 
(N.S.) 
n= 3 
r
2
= 0.66 
slope= 
-0.033 
(N.S.) 
n=8 
r
2
=0.09 
slope= 
0.002 
(N.S.) 
n=12 
r
2
<0.001 
slope 
<0.001 
(N.S.) 
n=3 
r
2
=0.49 
slope= 
-0.016 
(N.S.) 
n=8 
r
2
=0.023 
slope=  
0.003 
(N.S.) 
n=12 
r
2
=0.006 
slope= 
-0.001 
(N.S.) 
logD7.4 n=12 
r
2
=0.4 
Slope = 
-0.04 
(0.027) 
n=13 
r
2
=0.08 
slope=  
 -0.16 
(N.S.) 
n=13 
r
2
=0.06 
slope= 
0.11 
(N.S.) 
n=3 
r
2
=0.8 
slope= 
-1.11 
(N.S.) 
n=8 
r
2
=0.12 
slope= 
0.14 
(N.S.) 
n=12 
r
2
=0.61 
slope= 
0.97 
(p=0.002) 
n=3 
r
2
=0.91 
slope= 
-0.66 
(p=0.18) 
n=8 
r
2
=0.77 
slope= 
1.06 
(p=0.004) 
n=12 
r
2
=0.25 
slope= 
0.55 
(N.S.) 
nRot n=12 
r
2
=0.006 
slope= 
-0.019 
n=13 
r
2
=0.01 
slope= 
-0.014 
n=13 
r
2
<0.001 
slope= 
-0.003 
n=3 
r
2
=0.04 
slope= 
-0.09 
n=8 
r
2
=0.07 
slope= 
0.04 
n=12 
r
2
<0.001 
slope= 
0.004 
n=3 
r
2
<0.003 
slope= 
-0.014 
n=8 
r
2
<0.001 
slope= 
-0.010 
n=12 
r
2
=0.009 
slope= 
0.03 
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(N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
HBA n=12 
r
2
=0.06 
slope= 
-0.007 
(N.S.) 
n=13 
r
2
=0.54 
slope  
=-0.138 
(0.004) 
n=13 
r
2
=0.014 
slope  
=0.017 
(N.S.) 
n=3 
r
2
=0.95 
slope = 
-0.63 
(0.13) 
n=8 
r
2
=0 
slope = 
0 
(N.S.) 
n=12 
r
2
=0.019 
slope = 
-0.07 
(N.S.) 
n=3 
r
2
=0.86 
slope = 
-0.33 
(N.S.) 
n=8 
r
2
=0.007 
slope = 
0.0625 
(N.S.) 
n=12 
r
2
=0.21 
slope = 
-0.205 
(N.S.) 
HBD n=12 
r
2
=0.013 
Slope = 
-0.017 
(N.S.) 
n=13 
r
2
=0.14 
Slope = 
-0.45 
(N.S.) 
n=13 
r
2
=0.012 
Slope = 
0.104 
(N.S.) 
n=3 
r
2
=0.22 
Slope = 
-1.1 
(N.S.) 
n=8 
r
2
<0.001 
Slope = 
-0.02 
(N.S.) 
n=12 
r
2
=0.006 
Slope = 
0.2 
(N.S.) 
n=3 
r2=0.37 
Slope = 
-0.8 
(N.S.) 
n=8 
r
2
=0.16 
Slope 
=1.2 
(N.S.) 
n=12 
r
2
=0.04 
Slope = 
-0.45 
(N.S.) 
clogP n=12 
r2=0.36 
Slope = 
-0.04 
(0.03) 
n=13 
r
2
<0.08 
Slope = 
0.15 
(N.S.) 
n=13 
r
2
<0.01 
Slope = 
-0.04 
(N.S.) 
n=3 
r
2
=0.84 
Slope = 
-1.6 
(0.25) 
n=8 
r
2
=0.18 
Slope = 
0.24 
(N.S.) 
n=12 
r
2
=0.36 
Slope = 
0.66 
(0.03) 
n=3 
r
2
=0.71 
Slope = 
-0.84 
(N.S.) 
n=8 
r
2
=0.72 
Slope = 
1.40 
(0.0069) 
n=12 
r
2
=0.54 
Slope = 
0.72 
(0.005) 
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Table 4.8  Comparison between CCB and other drug classes as a function of logD7.4 
 
Class of Compounds fu Log Vdss
u
 Log CLtot
u
 Log CLren
u
 Log CLnonren
u
 
 [%] [l/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] 
           
Opioids
21 
 
 
 
n = 20 n = 19 n = 20 n = 10 n = 10 
r
2 
= 0.49 r
2 
= 0.50 r
2 
= 0.35 r
2 
= 0.02 r
2 
= 0.88 
Slope = -0.13 Slope = 0.30 Slope = 0.20 Slope = 0.01 Slope = 0.34 
p < 0.05 p < 0.05 p < 0.05 N.S p < 0.05 
β- ARLs21 
 
 
 
n = 30 n = 30 n = 30 n = 26 n = 26 
r
2 
= 0.64 r
2 
= 0.77 r
2 
= 0.66 r
2 
= 0.05 r
2 
= 0.51 
Slope = -0.22 Slope = 0.45 Slope = 0.42 Slope = -0.09 Slope = 0.52 
p < 0.05 p < 0.05 p < 0.05 N.S p < 0.05 
Benzodiazepines
45 
 
 
 
n = 17 n = 16 n = 17 n = 8 n = 8 
r
2
 = 0.51 r
2
 = 0.57 r
2
 = 0.19 r
2
 = 0.23 r
2
 = 0.81 
Slope = -0.20 Slope = 0.60 Slope = 0.28 Slope = -0.37 Slope = 0.66 
p < 0.05 p < 0.05 N.S N.S p < 0.05 
CCB (without 
Amlodipine) 
 
n = 12 n = 12 n = 12 n = 3 n = 8 
r
2 
= 0.40 r
2
 = 0.25 r
2
 = 0.61 r
2
 = 0.91 r
2
 = 0.77 
Slope = -0.04 Slope = 0.55 Slope = 0.97 Slope = -0.66 Slope = 1.06 
p < 0.027 N.S p<0.002 N.S (p=0.004) 
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Appendix I 
Summary of PK variables across studies  
(final values including ± SD for  CLtot,  and Vdss) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 68 
 
Amlodipine 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Stopher et 
al (88)
49 
H n=2 70 0.07 Bolus 0-250 GC-
ECD 
0.2 NCA* 27 7 19.74 
Faulkner et 
al (86)
50 
H n=12 
(26) 
66.6 0.15 10 0.1-144 GC-
ECD 
0.2 NCA* 40 6.89 20.55 
Vincent et 
al (00)
51 
H n=20 
(32) 
70 0.14 10 0-216 GC-
ECD 
0.2 NCA* 34.8 6.93 21 
Final values including ± SD (n=) for  CLtot,  and Vd 
6.94±0.06 (n=3) 20.43±0.64 (n=3) 
(a) Assume 70 kg as body weight, (*) calculated using graph 
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Bepridil 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
 (ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Lesko et al 
(86)
54 
P
b
 n=16 
(55) 
75 0.05 30 0-24 HPLC 
 
 
5 NCA 2478 5354 8.7 10.1 14.9 
(b) Post-operative patient with normal function liver and kidney 
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Clevidipine 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
 (ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Ericsson
 
et 
al (99)
56 
H 25 
(29) 
75 0.001-
0.44 
 0.75 GC-MS 2.2 Compart  121 0.56 
Ericsson et 
al (99)
57 
H 12 
(26) 
66.6 0.36 60 0-1.5 
 
GC-MS 0.46 Compart 37 142 0.58 
Final values including ± SD (n=) for  CLtot,  and Vd 131.50±14.8 (n=2). 0.57±0.01 (n=2) 
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Diltiazem 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Smith et 
al(1983)
59 
H n=8 
(22-58) 
84 0.24 10 0-48 HPLC 10 Compart 294 10.4 3.18 
Bianchetti 
et  al 
(95)
60 
H n=24 
(25.5) 
72.4 0.30 30 0-36 GC-
MS. 
5 Compart 168 9.21.2 1.94 
Tawashi 
(91)
61 
H n=3 
(27.3) 
69.8 0.29 5 0-48 HPLC-
UV 
2.5 Compart 124 122  
NCA 124 12.6 3.21 
Ochs et 
al(1984)
62 
H n=6 
(25) 
70 0.28 20 0-36 GC 
ELD 
5 NCA* 179 11.26 2.51 
Final values including ± SD (n=) for  CLtot,  and Vd 10.87±1.4(n=4) 2.7±0.6(n=4) 
(*) calculated using graph 
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Felodipine 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Edgar et 
al(1985)
64 
 
H n=8 
(25 y) 
74 0.034 
 
 
30 0-30 
 
GC W/ 
ELD 
0.76 
 
Compart 
 
25.6 11.1  
NCA 25.6 6.4 5.8 
Lundahl 
et 
al(1997)
65 
H 
n=12 
(25 ) 
75 0.02 60 0-24 GC W/ 
ELD 
0.76 Compart 
 
12.5 
 
11.2 NA 
Edgar et 
al(1987)
66 
H 
n=10 
26 
73 0.014 
 
 
20 0-10 GC W/ 
ELD 
0.76 Compart 12.38 14.9 NA 
Edgar et 
al(1987)
66 
H 
n=10 
(26y ) 
73 0.04 20 0-10 GC W/ 
ELD 
0.76 Compart 37.05 14.3 2.93(cal) 
Landehal 
(1988)
67 
H 
n=12 
(26) 
75 0.0005 5 0-27 HPLC-l 
sci. 
0.9 
 
NCA 2 12.5 10.33.4 
Final values including ± SD (n=) for  CLtot,  and Vd 11.86±3.4(n=5) 8.05±3.7(n=3) 
(a) Assume 70 kg as body weight, (*) calculated using graph 
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Fendiline 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
 (ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Kukovetz et 
al (82)
69 
H n=6 
(23) 
66 0.05 Bolus 0-48 
TLC 
 
 
5 NCA* 4.2 2616 17.4 13.8 10.55 
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Isradipine 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Christensen 
et al 
(2000)
70 
H 
n=10 
(24.2) 
71.9 (0.026) 1mg/60m 
& 
0.9mg/3h 
0-10 GC-
NSD 
0.2   
NCA* 
  
7 
  
15.6 
  
1.43 
 
Carrara et 
al (1994)
71 
H 
n=10 
7211 (0.014) 5 0-24 RIA 0.03  
NCA* 
 
128 
 
5.84 
 
0.65 
Cotting et 
al (1990)
72 
H n=7 
(43) 
70 0.014 10 0-28 GC-
MS 
0.2 Compart NA 15.53 NA 
Final values including ± SD (n=) for  CLtot,  and Vd 12.3 ±5.6(n=3) 1.04 ±0.5(n=3) 
Radioimmuno Assay (RIA), (a) Assume 70 kg as body weight, (*) calculated using graph 
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Mibefradil 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
 (ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Welker et al 
(98)
74 
H n=18 
(26.5) 
70 
0.28 30 
 
0-250 HPLC 2 NCA 110 4.07 2.8 
0.57       3.44 3.0 
1.14       3.58 2.5 
Final values including ± SD (n=) for  CLtot,  and Vd  3.7±0.3(n=5) 2.7 ±0.3(n=3) 
(a) Assume 70 kg as body weight, (*) calculated using graph 
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Nicardipine 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Graham 
et al(85)
76 
H n=5 70 0.21 180 0-12 GC, HPLC 2-3  Compart 121 8.23  
NCA* 121 8.12 0.68 
Guerret et 
al (89)
77 
H n=6 72 0.02 5   0-12 GC-MS 0.05 Compart 11.30.98 10.16 
Higuci et 
al (80)
78 
H n=2 59 0.01 5   0-2 GC W/ 
ELD 
2-3  NCA 24 7  
NCA* 24 8.15 0.54 
Higuci et 
al (80)
78 
H n=2 59 0.02 5   0-2 GC W/ 
ELD 
2-3  NCA 74 9  
NCA* 74 8.22 0.45 
Campbell 
et al(85)
79 
H 
n=14 
(30) 
70
a 
0.16 1 0-6 HPLC/GC-
ECD 
5 Compart 160 17 0.89 
Final values including ± SD (n=) for  CLtot,  and Vd 10.56±3.8 (n=5) 0.71 ±0.23 (n=5) 
(a) Assume 70 kg as body weight, (*) calculated using graph 
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Nifedipine 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Foster 
et al(83)
81 
H n=9 
(25 ) 
75.3 0.013 
 
 
5 -50m to 
+ 
30 hr 
 
GC W/ 
ELD 
1 
 
NCA 25.97 
4.81 
10.33±1.5 1.12± 
0.14 
Ramsch et 
al(86)
82
 
H n=7 70
a 
0.024 4-5 0-8 GC W/ 
ELD 
1 Compart 102 7.64 0.47 
Kleinbloesem 
(85)
83 
H n=5 
(44) 
80 0.056 45 0-8 HPLC-
UV 
5 Compart 118 6.8±1.6 0.78±0.2.3 
Rashid et al 
(95)
84 
H n=8 
cau 
(22) 
74 0.033 2.5 0-12  HPLC-
UV 
3 
NCA 
92 8.5 0.97 
Bortel et al(89)
85 H n=6 
(44) 
75.5 0.058 60 0-8 HPLC-
UV 
3 NCA NA 6.47 NA 
Robertson et al 
(88)
86 
H n=5 
(27) 
75 0.033 5 0-6 HPLC-
UV 
3 NCA 110 6.92 0.76 
Kleinbloesem 
(84)
87 
H n=5 
(42) 
75 0.06 50 0-7 
 
 
HPLC-
UV 
2 Compart 118 6.8±1.6 0.78±0.2.3 
Waller (84)
88 
H n=7 
(26) 
75 0.046 4 0-8 HPLC-
UV  
3 NCA* 245 6.1 0.71 
Final values including ± SD (n=) for  CLtot,  and Vd 7.44±1.3 (n=8) 0.66 ±0.3 (n=7) 
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Nimodipine 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Ramsch 
et al 
(86)
82 
H n=6 70
a 
0.03 4-5 0-6 GC 
W/ 
ELD 
0.5 Compart 92 144 0.940.41 
Ramsch 
et al  
(86)
82 
H n=2 70
a 
0.34 24 h 0-30 HPLC 0.5 Compart 12 18.7 2.3 
Mck et al 
(96)
89 
H n=24 
(30) 
66.4 0.015 60 0-24 GC-
ECD 
0.1 NCA 11.34 16.6 1.21 
Final values including ± SD (n=) for  CLtot,  and Vd 16.4±2.35 (n=3) 1.48 ±0.7 (n=3) 
(a) Assume 70 kg as body weight, (*) calculated using graph 
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Nisoldipine 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Durat
ion 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Van 
harten et 
al (88)
91 
8H(54) 74 0.374 40 0-32 GC 
ELD 
0.25 NCA 5.21.1 11.44.1 4.12.1 
Van 
harten et 
al (89)
92 
6 
Hyperte
nsion 
(62) 
87 0.022 120 0-24 GC 
ELD 
0.25 NCA 5.7 11.7 5.91.8 
Ahr et al 
(1987)
93 
4H 70
a 
0.08 1200 0-44 GC-
MS/ECD 
0.2 Compart 6.221 11.31.8 2.71.2 
Final values including ± SD (n=) for  CLtot,  and Vd 11.3±0.37 (n=3) 3.6 ±1.9 (n=3) 
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Nitrendipine 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
 
Ramsch et 
al (86)
82 
H n=9 70 0.04 3-5 0-6 GC 
W/ 
ELD 
0.5 Compart 9.7 34.516.6 6.65.5 
Mikus et al 
(87)
96 
H n=6 
(27) 
70 0.028 30 0-25.5 CG-
SIM 
0.1 Compart 10.97 18.653.59 5.392.35 
Dylewicz et 
al (87)
97 
H n=6 69.7 0.07 3-5 0-48 GC 
W/ 
ELD 
 
0.5 
Compart 14 18.5 NA 
Soon & 
Breimer 
(91)
98 
H n=9 
(24) 
74 0.04 4 0-12 GC-
ECD 
0.2 NCA& 
Compart 
 
NA 
213.4 3.791.32 
Graefe et al 
(88)
99 
H n=9 
(25) 
75 0.04 4 0-6 GC-
ECD 
0.5 NCA NA 32.2(20-52) 3.6 
Final values including ± SD (n=) for  CLtot,  and Vd 24.9±7.7 (n=5) 4.8 ±2.5 (n=4) 
SIM: Single Ion Monitoring 
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Verapamil 
 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
Freedman 
et al(81)
100 
4healthy 
2patients
(47) 
79 0.16 10-15 0-14 HPLC 2 Compart 200 10.94 3.4 
Dominic et 
al(81)
101 
8H(26) 71 0.2 3-5 0 -6 GC with 
thermo 
-ionic det. 
5 Compart 274 14.93.8 
 
2.52 
 Abernethy 
et al(85)
102 
 
 
7(29) 
Hyperten
sion P 
(no-med) 
76 0.13 10 0-24 GC-NPD 2 Compart 180 15.54.5 4.31.1 
Eichelbau
m et 
al(81)
103 
6H(23) 86 0.15 5 0-13 mass 
fragmen-
tography 
2.2 Compart 31 19.67 6.15 
Eichelbau
m et 
al(84)
104 
5H(25) 69 0.14 5 0-12 mass 
fragmen-
tography 
2.2 Compart 270 14.27 3.4 
Final values including ± SD (n=) for  CLtot,  and Vd 15.1±3.1 (n=5) 4.0 ±1.4 (n=5) 
NPD=Nitrogen Phosphorous Detection, h=healthy volunteers, p= patient 
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Amlodipine 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Stopher et 
al (88)
49 
H n=2 70 0.07 Bolus 0-250 GC-
ECD 
0.2 NCA* 27 9445 7 19.74 35 
Faulkner et 
al (86)
50 
H n=12 
(26) 
66.6 0.15 10 0.1-144 GC-
ECD 
0.2 NCA* 40 21802 6.89 20.55 40.65 
Vincent et 
al (00)
51 
H n=20 
(32) 
70 0.14 10 0-216 GC-
ECD 
0.2 NCA* 34.8 21480 6.93 21 38.3 
(a) Assume 70 kg as body weight, (*) calculated using graph 
Plasma protein binding studies: 
Reference   Range (ng/ml) Method   Assay Protein binding 
Stopher et al (88)
52 
  50  Equilibrium dialysis Liquid 
Scintillation 
98% 
Urine excretion study: 
 Beresford et al (1988)53 
 Determination of amlodipine in urine indicated that 4% of the dose to the human volunteers was excreted unchanged via the 
kidneys during the 0-72 h period after dosing. 
 This study overestimate fe because the accumulative amount of urine was not collected for a long period of time (4-5 t1/2) and they 
only collect for three days and then extrapolated  
 Only two healthy volunteers were used in this study   
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Bepridil 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
 (ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Lesko et al 
(86)
54 
P
b
 n=16 
(55) 
75 0.05 30 0-24 HPLC 
 
 
5 NCA 2478 5354 8.7 10.1 14.9 
(b) Post-operative patient with normal function liver and kidney 
Plasma protein binding studies: 
 
Reference   Range (ng/ml) Method   Assay Protein binding 
Pritchard et al (98)
55 
  200-4000 Equilibrium dialysis Liquid 
Scintillation 
99.76% 
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Clevidipine 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
 (ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Ericsson
 
et 
al (99)
56 
H 25 
(29) 
75 0.001-
0.44 
 0.75 GC-MS 2.2 Compart   121 0.56 0.15 
Ericsson et 
al (99)
57 
H 12 
(26) 
66.6 0.36 60 0-1.5 
 
GC-MS 0.46 Compart 37 2535 142 0.58 0.25 
 
Plasma protein binding studies: 
 
 Reference Range (ng/ml) Method Protein binding 
Ericsson et al (99)
58 
  11.4-114  HPLC  99.68% 
Urine excretion study: 
 Ericsson et al (99)57 
 Samples of urine were collected pre-dose and up to 168 h after the start of the clevidipine infusion. The sampling intervals 
were 24 h, except for the first investigational day, when urine was collected during intervals of 0-3, 3-6, 6-12 h and 12- 24 h 
after start of infusion.  
 No parent drug was found in the urine. 
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Diltiazem 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Smith et 
al(1983)
59 
H n=8 
(22-58) 
84 0.24 10 0-48 HPLC 10 Compart 294 21000 10.4 3.18 4.451.5 
Bianchetti 
et  al (95)
60 
H n=24 
(25.5) 
72.4 0.30 30 0-36 GC-
MS. 
5 Compart 168 336603720 9.21.2 1.94 3.60.3 
Tawashi 
(91)
61 
H n=3 
(27.3) 
69.8 0.29 5 0-48 HPLC-
UV 
2.5 Compart 124 244804020 122  2.70.41 
NCA 124 22710 12.6 3.21 4.44 
Ochs et 
al(1984)
62 
H n=6 
(25) 
70 0.28 20 0-36 GC 
ELD 
5 NCA 179 24844 11.5±0.72  11.2 
NCA* 179 23345 11.26 2.51 3.78 
       Compart    5.2  
(*) calculated using graph 
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Plasma protein binding studies: 
 
Reference   Range Method Assay Protein binding 
Bloedow et al 
(1985)
63 
30-2060 ng/ml Equilibrium dialysis Liquid 
scintillation 
80 
 
Urine excretion study: 
 Tawashi et al (1991)61 
 Urine collection (0-6, 6-12, 12-24, and 24-48 h) 
 The unchanged drug in the urine was 6.6% (CLren=53 ml/min) 
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Felodipine 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Edgar et 
al(1985)
64 
 
H n=8 
(25 y) 
74 0.034 
 
 
30 0-30 
 
GC W/ 
ELD 
0.76 
 
Compart 
 
25.6 3050 11.1  10.21 
 
NCA 25.6 5272 6.4 5.8 10.37 
Lundahl 
et 
al(1997)
65 
H 
n=12 
(25 ) 
75 0.02 60 0-24 GC W/ 
ELD 
0.76 Compart 
 
12.5 
 
1890 
 
11.2 NA 2.9 
Edgar et 
al(1987)
66 
H 
n=10 
26 
73 0.014 
 
 
20 0-10 GC W/ 
ELD 
0.76 Compart 12.38 934 
 
14.9 NA NA 
Edgar et 
al(1987)
66 
H 
n=10 
(26y ) 
73 0.04 20 0-10 GC W/ 
ELD 
0.76 Compart 37.05 2886 
 
14.3 2.93(cal) NA 
Landehal 
(1988)
67 
H 
n=12 
(26) 
75 0.0005 5 0-27 HPLC-l 
sci. 
0.9 
 
NCA 2 50.7 12.5 10.33.4 NA 
(c) Assume 70 kg as body weight, (*) calculated using graph 
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Plasma protein binding studies: 
 
Reference   Range  (ng/ml) Method Assay Protein binding 
Valle et al(96)
68 
 
1.15-25 Ultrafiltration Liquid 
scintillation 
99.65% 
Ericsson et al(99)
58 
9.6  Liquid 
Chromatography 
99.60% 
Urine excretion study: 
 Edgar et al (1985)64 
 Urine was quantitatively collected for 72 hours at the following times: blank, 0 to 4, 4 to 8,  8 to 12, 12 to 
24, 24 to 36, 36 to 48, 48 to 60, and 60 to 72 hours. The unchanged drug in the urine was not observed.  
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Fendiline 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
 (ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Kukovetz et 
al (82)
69 
H n=6 
(23) 
66 0.05 Bolus 0-48 TLC 
 
 
5 NCA* 4.2 2616 17.4 13.8 10.55 
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Isradipine 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Christensen 
et al 
(2000)
70 
H 
n=10 
(24.2) 
71.9 (0.026) 1mg/60m 
& 
0.9mg/3h 
0-10 GC-
NSD 
0.2   
NCA* 
  
7 
  
1694 
  
15.6 
  
1.43 
 
  
1.33 
Carrara et 
al (1994)
71 
H 
n=10 
7211 (0.014) 5 0-24 RIA 0.03  
NCA* 
 
128 
 
2383 
 
5.84 
 
0.65 
 
5.03 
Cotting et 
al (1990)
72 
H n=7 
(43) 
70 0.014 10 0-28 GC-
MS 
0.2 Compart NA 942132 15.53 NA 5.12.4 
Radioimmuno Assay (RIA), (a) Assume 70 kg as body weight, (*) calculated using graph 
Plasma protein binding studies: 
Reference   Range (ng/ml) Method   Assay Protein binding (%) 
Pinquier et al 
(1988)
73 
 
(0.37-3.7) Equilibrium dialysis Liquid 
Scintillation 
97.5 
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Mibefradil 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
 (ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Welker et al 
(98)
74 
H n=18 
(26.5) 
70 0.28 30 
 
0-250 HPLC 2 NCA 110 68796 4.07 2.8 12.3 
0.57  165697 3.44 3.0 14.8 
1.14  318435 3.58 2.5 10.3 
(a) Assume 70 kg as body weight, (*) calculated using graph 
Plasma protein binding studies: 
Reference   Range (ng/ml) Method   Assay Protein binding 
Horst & Welker 
(98)
75 
  500-1000 Equilibrium dialysis Liquid 
Scintillation 
99.6% 
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Nicardipine 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Graham 
et al(85)
76 
H n=5 70 0.21 180 0-12 GC, HPLC 2-3  Compart 121 26037 8.23  
 
4.75 
NCA* 121 26376 8.12 0.68 1.40 
Guerret et 
al (89)
77 
H n=6 72 0.02 5   0-12 GC-MS 0.05 Compart 2280 11.30.98 10.16 4.11.6 
Higuci et 
al (80)
78 
H n=2 59 0.01 5   0-2 GC W/ 
ELD 
2-3  NCA 24 1400 7  1.05 
NCA* 24 1227 8.15 0.54 0.83 
Higuci et 
al (80)
78 
H n=2 59 0.02 5   0-2 GC W/ 
ELD 
2-3  NCA 74 2300 9  0.83 
NCA* 74 2433 8.22 0.45 0.83 
Campbell 
et al(85)
79 
H 
n=14 
(30) 
70
a 
0.16 1 0-6 HPLC/GC-
ECD 
5 Compart 160 9411.7 17 0.89 0.97 
 
 
 
(a) Assume 70 kg as body weight, (*) calculated using graph 
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Plasma protein binding studies: 
Reference   Range (ng/ml) Method   Assay Protein binding (%) 
Urien et al (1985)
80 
 
 1000-40000 Equilibrium dialysis Liquid 
scintillation 
 98.92 
 
Urine excretion study: 
 
 Garham et al (1985)76 
The unchanged drug in the urine was not observed 
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Nifedipine 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Foster 
et al(83)
81 
H n=9 
(25 ) 
75.3 0.013 
 
 
5 -50m to 
+ 
30 hr 
 
GC W/ 
ELD 
1 
 
NCA 25.97 
4.81 
1584.6± 
223 
10.33±1.5 1.12± 
0.14 
1.77±0.25 
Ramsch et 
al(86)
82
 
H n=7 70
a 
0.024 4-5 0-8 GC W/ 
ELD 
1 Compart 102 39241824 7.64 0.47 2.5±2.4 
Kleinbloesem 
(85)
83 
H n=5 
(44) 
80 0.056 45 0-8 HPLC-
UV 
5 Compart 118 8230 6.8±1.6 0.78±0.2.3 1.76±0.4 
Rashid et al 
(95)
84 
H n=8 
cau 
(22) 
74 0.033 2.5 0-12  HPLC-
UV 
3 
NCA 
92 4440 8.5 0.97 1.7±0.5 
Bortel et al(89)
85 H n=6 
(44) 
75.5 0.058 60 0-8 HPLC-
UV 
3 NCA NA 11000 6.47 NA 4.08±1.1 
Robertson et al 
(88)
86 
H n=5 
(27) 
75 0.033 5 0-6 HPLC-
UV 
3 NCA 110 5040 6.92 0.76 1.9 
Kleinbloesem 
(84)
87 
H n=5 
(42) 
75 0.06 50 0-7 
 
 
HPLC-
UV 
2 Compart 118 8181 6.8±1.6 0.78±0.2.3 1.76±0.4 
Waller (84)
88 
H n=7 
(26) 
75 0.046 4 0-8 HPLC-
UV  
3 NCA* 245 7648 6.1 0.71 1.92 
(a) Assume 70 kg as body weight, (*) calculated using graph 
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Plasma protein binding studies: 
Reference Range Method   Assay Protein binding (%) 
Kleinbloesem (85)
83 
5-200ng/ml Mem dialysis after 
centrifugation 
 Liquid 
scintillation 
96 
Bortel(89)
85 
NA Equilibrium dialysis Liquid 
scintillation 
95.5 
Urine excretion study: 
 Ramach et al (1986)82 
 Using Gas Chromatographic with ELD(5 ng/ml) 
 The unchanged drug in the urine was not observed   
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Nimodipine 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Ramsch 
et al 
(86)
82 
H n=6 70
a 
0.03 4-5 0-6 GC 
W/ 
ELD 
0.5 Compart 92 2328798 144 0.940.41 1.10.2 
Ramsch 
et al  
(86)
82 
 
H n=2 70
a 
0.34 24 h 0-30 HPLC 0.5 Compart 12 18181
 
18.7 2.3 1.5 
Mck et al 
(96)
89 
H n=24 
(30) 
66.4 0.015 60 0-24 GC-
ECD 
0.1 NCA 11.34 960 16.6 1.21 1.4 
(a) Assume 70 kg as body weight, (*) calculated using graph 
Plasma protein binding studies:  
 Ramach et al (1985)90 
Plasma protein binding is 98% 
Urine excretion study: 
 Ramach et al (1985)90 
The unchanged drug in the urine was not observed using HPLC 
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Nisoldipine 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Durat
ion 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Van 
harten et 
al (88)
91 
8H(54) 74 0.374 40 0-32 GC 
ELD 
0.25 NCA 5.21.1 32807 11.44.1 4.12.1 9.75.4 
Van 
harten et 
al (89)
92 
6 
Hyperte
nsion 
(62) 
87 0.022 120 0-24 GC 
ELD 
0.25 NCA 5.7 1880 11.7 5.91.8 15.46.7 
Ahr et al 
(1987)
93 
4H 70
a 
0.08 1200 0-44 GC-
MS/ECD 
0.2 Compart 6.221 7079 11.31.8 2.71.2 10.71.3 
Plasma protein binding studies: 
Reference   Range (ng/ml) Method   Assay Protein binding (%) 
Boelaert et al 
(1988)
94 
 
100ng/ml Ultrafiltration LC 99.60.04 
Ahr et al (1987)
93 
20-1000 Ultrafiltration LC 99.7 
Urine excretion study: 
 Scherling et al (1987)95 
 Urine collection: 0-4, 4-8, 8-12, 12-24 hr. 
 The unchanged drug in the urine was not observed   
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Nitrendipine 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Ramsch et 
al (86)
82 
H n=9 70 0.04 3-5 0-6 GC 
W/ 
ELD 
0.5 Compart 9.7 15121092 34.516.6 6.65.5 4.62.4 
Mikus et al 
(87)
96 
H n=6 
(27) 
70 0.028 30 0-25.5 CG-
SIM 
0.1 Compart 10.97 1662333.6 18.653.59 5.392.35 8.564.16 
Dylewicz et 
al (87)
97 
H n=6 69.7 0.07 3-5 0-48 GC 
W/ 
ELD 
 
0.5 
Compart 14 3708288 18.5 NA 2.190.45 
 
Soon & 
Breimer 
(91)
98 
H n=9 
(24) 
74 0.04 4 0-12 GC-
ECD 
0.2 NCA& 
Compart 
 
NA 
1904 213.4 3.791.32  
41.6 
 
Graefe et al 
(88)
99 
H n=9 
(25) 
75 0.04 4 0-6 GC-
ECD 
0.5 NCA NA 1242 32.2(20-52) 3.6 2.9 
SIM: Single Ion Monitoring 
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Plasma protein binding studies: 
Reference   Range Method   Assay Protein binding 
Mikus et al (1987)
96 
 
   Equilibrium dialysis Liquid 
Scintillation 
 96.4-98.9 
Dylewicz et al 
(1987)
97 
 Equilibrium dialysis Liquid 
Scintillation 
97.90.4 
 
Urine excretion study: 
 Mikus et al (1987)96 
 Urine collection: 0-4, 4-8, 8-12, 12-24, 24-48 hr. 
 Less than 0.5% of the dose excreted as unchanged drug in urine 
 Nitrendipine could not be detected in urine (Dylewicz et al (1987)97 
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Verapamil 
 
Reference 
Sample 
size 
(Age) 
BW 
(kg) 
Dose 
(mg/kg) 
 
Duration 
(min) 
Sampling 
Schedule 
(hrs) 
Assay LLOQ 
Plasma 
PK 
Analysis 
PK endpoints 
     Plasma 
 
 ng/ml  Cmax 
(ng/ml) 
AUC 
(ng*min/ml) 
 
CLtot 
(ml/min/kg) 
Vdss 
(l/kg) 
t1/2 
(h) 
Freedman 
et al(81)
100 
4healthy 
2patients
(47) 
79 0.16 10-15 0-14 HPLC 2 Compart 200 15060 
3300 
10.94 3.4 5 
Dominic et 
al(81)
101 
8H(26) 71 0.2 3-5 0 -6 GC with 
thermo 
-ionic det. 
5 Compart 274 13422.8 14.93.8 
 
2.52 1.84 
0.4 
 Abernethy 
et al(85)
102 
 
 
7(29) 
Hyperten
sion P 
(no-med) 
76 0.13 10 0-24 GC-NPD 2 Compart 180 8520 
2280 
15.54.5 4.31.1 3.81.1 
 
 
 
Eichelbau
m et 
al(81)
103 
6H(23) 86 0.15 5 0-13 mass 
fragmen-
tography 
2.2 Compart 31 7949 19.67 6.15 3.69 
 
 
 
Eichelbau
m et 
al(84)
104 
5H(25) 69 0.14 5 0-12 mass 
fragmen-
tography 
2.2 Compart 270 10101 14.27 3.4 3.75 
 
 
 
NPD=Nitrogen Phosphorous Detection, h=healthy volunteers, p= patient 
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Plasma protein binding studies: 
Reference   Range ng/ml Method   Assay Protein binding 
Schomerus et 
al(1976)
105 
 
 50- 500 Equilibrium dialysis  Liquid 
scintillation 
  90.35% 
Keefe et al(1980)
106 
 
35 -1,557  Equilibrium dialysis Liquid 
scintillation 
89.6 ± 0.17% 
 
 
Urine excretion study: 
 Toffoli et al (1987)107 
 Urine collection: every 12 hr. 
 The unchanged drug in the urine was 2%   
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